Tumor-associated macrophages in colon cancer immunotherapy: mechanisms, natural product interventions, and microenvironment remodeling

Abstract

Colon cancer persists as a major global health burden due to therapy resistance and metastasis, with tumor-associated macrophages (TAMs) in the microenvironment driving progression through immune evasion and angiogenesis. This review highlights plant-derived therapeutics targeting TAMs to disrupt protumor signaling. Key phytochemicals (e.g., Curcumin, Cucurbitacin B, Astragaloside IV) suppress M2 polarization via NF-κB/STAT3 inhibition, block VEGF/HIF-1α-mediated angiogenesis, and enhance antitumor immunity by downregulating PD-L1. Cannabidiol, Hydroxygenkwanin regulate TAM metabolism. Dietary agents like sulforaphane and β-glucans modulate TAM-gut microbiome crosstalk. Nanoparticle-encapsulated phytochemicals enhance TAM-targeted delivery, while clinical translation requires standardized phytopreparations and biomarker-guided trials. We propose integrating validated botanical adjuvants (e.g., Fucoidan for TLR4 inhibition, dihydroisotanshinone I for CCL2 suppression) with immunotherapies to remodel immunosuppressive niches. Phytotherapy offers a multifaceted strategy to overcome TAM-driven therapeutic barriers in colon cancer, emphasizing plant-based precision medicine to augment conventional treatments.

1 Introduction

Colon cancer is the fourth most lethal malignancy worldwide. It is estimated that there will be 2 million new cases of colorectal cancer globally in 2020 By 2040, it is projected to reach 3.2 million new cases, with the greatest relative increase occurring in countries in transition and in younger age groups, resulting in a significant burden of disease (1). Despite efforts to lower the screening age and implement early interventions in certain countries, the high fatality rate of colon cancer remains a daunting challenge.

Currently, treatments for colon cancer include surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy, however, the efficacy is limited and there are many adverse effects (2, 3). For instance, although chemotherapeutic drugs like 5-Fluorouracil (5-FU) demonstrate evident anticancer efficacy, their detrimental side effects including neurological symptoms, bone marrow suppression, and gastrointestinal reactions intensify patients’ discomfort. Moreover, the development of drug resistance has further compounded the constraints of their clinical utilization (4). Immunotherapy has shown unique advantages in current cancer therapies, especially immune checkpoint inhibitors. The US Food and Drug Administration (FDA) approved anti-PD-1 (Pembrolizumab and Nivolumab) as monotherapy or in combination with cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) inhibitor (Ipilimumab) for the treatment of colon cancer with high microsatellite instability (MSI-H) or mismatch repair deficiency (DMMR), unfortunately, only 5-15% of colon cancer patients benefit (5, 6). New drug development against colon cancer is challenging given the limited efficacy of current treatments and the inevitable off-target effect (7).

Natural products are widely sourced and structurally diverse, with excellent pharmacological activity, demonstrating significant advantages in the treatment of colorectal cancer. Several synthetic derivatives derived from natural products have been used in clinical anti-cancer treatments, such as the semi-synthetic water-soluble camptothecin derivative, irinotecan (8). Many botanical active compounds have shown anti-colon cancer activity, including improving the tumor inflammatory microenvironment, inhibiting tumor cell proliferation, migration, and angiogenesis, as well as regulating the gut microbiota (9–11).

It is known that tumor microenvironment (TME) is critical for cancer progression, of which immune cell subsets are key components. Macrophages, as important members of the immune system, are involved in inflammatory responses and immune regulation, while dynamically changing in response to various signals in TME (12, 13). Studies have shown that in mouse models of colon cancer, macrophages may lose their ability to phagocytose tumor cells and even be used by tumor cells to promote their growth and proliferation (14, 15). Targeted regulation of the activity of macrophages, promotion of its phagocytosis of tumor cells and immunomodulatory function has become a new research hotspot in current cancer therapy. Moreover, because of the stability of the genome of macrophages, they are relatively less likely to develop drug resistance compared to tumor cells (16). Existing reports have found that natural compounds such as Astragaloside, Curcumin can exert anti-colorectal cancer effects by modulating macrophage activity (17, 18). Further investigation into the immune regulatory roles of phytochemicals will help provide more effective treatment options for colon cancer patients. Therefore, this review summarizes the mechanisms by which macrophages are involved in the development of colon cancer and the potential strategies of targeting macrophages with natural products for the treatment of colon cancer.

2 Overview of macrophages

2.1 Basic biological characteristics of macrophages

Macrophages are innate immune cells of bone marrow and embryonic origin that phagocytose foreign substances or their own components and present them to T cells to activate adaptive immune responses. In addition, macrophages also participate in tissue homeostasis, repair and remodeling by expressing a variety of receptors, cytokines, chemokines, and protein hydrolases (19).

Depending on the tissue-specific microenvironmental signals macrophages acquire different phenotypes, mainly including M1 phenotype (classical activation) and M2 phenotype (alternative activation) (20, 21). M1 macrophages can be activated by bacterial lipopolysaccharide (LPS) and type 1 helper T (Th1) cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), releasing pro-inflammatory cytokines e.g., interleukin(IL)-1β, IL-6, IL-12, and TNF-α, as well as chemokines e.g., C-X-C Motif Chemokine Ligand (CXCL) 9 and CXCL10, and it is capable of presenting antigens via MHC class II molecules (20, 22). M1 macrophage surface markers mainly include CD80, CD86 and CD16/32. M1 macrophages are often considered to have proinflammatory, antitumor, and adaptive immune activation capabilities (23, 24).

M2 macrophages can be activated by Th2-type cytokines IL-4 and IL-13, producing anti-inflammatory factors such as IL-10 and Transforming growth factor beta (TGF-β), as well as chemokines e.g., C-C Motif Chemokine Ligand (CCL)1, CCL17, CCL18, CCL22, and CCL24, with surface markers CD163, CD206, and CD209 (25). M2 macrophages have the function of promoting the resolution of inflammation and participate in tissue repair through angiogenesis at the later stages of inflammation (26–28). Polarized M2 macrophages are divided into M2a, M2b, M2c and M2d subpopulations. The characteristics of the different subtypes of M2 macrophages are listed in Table 1. M2a and M2b types are involved in immune regulation by promoting the Th2 cell response, while the M2c type is associated with immune response suppression and tissue remodeling (43). The M2d type is activated mainly by tumor cells, tumor-associated factors, or chemotherapeutic agents, and is sometimes referred to as TAMs. This type of macrophage has immunosuppressive and tumor-promoting functions (44, 45) and specifically expresses IL-10. and vascular endothelial growth factor (VEGF) to participate in tumor progression and angiogenesis (44, 46) (Figure 1A).

Figure 1

2.2 Polarization of tumor-associated macrophages

TME serves as the internal environment in which tumor cells are produced and live and regulates tumor initiation and progression. It consists of non-cancerous cells (a variety of immune cells, cancer-associated fibroblasts, endothelial cells), as well as non-cellular components (cytokines, chemokines, proteins, extracellular vesicles, etc.) (47), and the network formed by these elements builds the tumor-promoting environment (48, 49). Monocytes in the peripheral blood are recruited into the highly structured TME and differentiate into TAMs under the influence of chemokines secreted by tumors, such as colony stimulating factor 1 (CSF-1), CCL2, and CCL5 (50, 51). Significant macrophage accumulation has been found in both tumor mouse models and tumor patient tissue samples (46, 52).

TAMs polarization is usually influenced by complex environmental factors in the TME, such as hypoxia, low pH and variable extracellular matrix (ECM) composition (53, 54). In fact, in the early stage of tumor, the immune system promotes macrophages and T cells to clear tumor cells to play anti-tumor and pro-immune response roles (55), and the majority of infiltrating macrophages at this stage are of the M1 phenotype and secrete pro-inflammatory factors (56). For example, granulocyte colony-stimulating factor (G-CSF) polarizes macrophages to a pro-inflammatory phenotype by promoting IL-10 production and reducing IL-12 in colon cancer TME (57). However, as the tumor progresses and the tumor cells continue to interact with the TME, most TAMs are “educated” to become “bad” macrophages that promote tumor growth and metastasis, and then the TAMs take on a predominantly M2 phenotype, creating an immunosuppressive environment and mediating the Th2 immune response (58). Although the M1/M2 polarization model offers a foundational framework for classifying macrophages, it falls short in capturing the phenotypic diversity and plasticity of TAMs. In recent years, researchers have employed surface markers such as F4/80⁺CD68⁺ and F4/80⁺CD206⁺ to delineate distinct TAM subsets (59). Complementing this approach, clustering analyses derived from single-cell RNA sequencing have identified four novel TAM subpopulations across various solid tumors: FCN1⁺, SPP1⁺, C1Q⁺, and CCL18⁺ macrophages. (60, 61). These advancements contribute to a more nuanced understanding of TAM lineage hierarchies and their functional heterogeneity within the tumor microenvironment. TAMs as one of the abundantly infiltrating immune cells in TME, affect tumor angiogenesis and lymphangiogenesis, tumor cell immune escape, immune regulation, and tumor invasion and metastasis (50, 62) (Figure 1A).

3 Core roles of TAMs in colon cancer progression

As described in the previous section, TAMs play an important role in the development of tumors. Current studies consider TAMs to be a diverse macrophage population with characteristics of both M1 and M2 subpopulations, rather than being categorized solely by M1/M2 phenotype. In different tumors, the plasticity of macrophages may enable them to play different roles. Several studies have confirmed that macrophage infiltration in the early stage of tumor invasion has a positive impact on the prognosis of colon cancer (63, 64). However, many studies now support the opposite view that TAMs promote malignant progression of colon cancer and play an immunosuppressive role in the TME of colon cancer, as we will describe below.

3.1 Promotion of tumor proliferation, invasion, and epithelial-mesenchymal transition

The inflammatory micro-environment involved and mediated by TAMs is closely related to the occurrence and development of colon cancer (65). Activation of cytokines and chemokines produced by chronic inflammation of tissues, as well as transcription factors such as nuclear factor kappa-B (NF-κB), signal transducer and activator of transcription 3 (STAT3), hypoxia-inducible factor 1α (HIF1α), promotes macrophage recruitment and initiates macrophage host responses (66–68).Macrophages subsequently produce inflammatory mediators (IL-6, TNF, IFN-γ), growth factors such as epidermal growth factor (EGF) and WNTs, proteases, reactive oxygen species (ROS), as well as nitric oxide (NO) that may activate proto-oncogenes to promote tissue carcinogenesis (69–71). Not only that, these substances produced by TAMs can also promote colon cancer growth. Studies have found that CCL2, IL-1α and IL-6 secreted by TAMs can promote the proliferation of colon cancer cells (72), and the release of the matrix metalloproteinase (MMP) 1 accelerates the transition of the tumor cell cycle from the G0/G1 phase to the S phase and G2/M phase (73).CSF1 is an important cytokine involved in macrophage proliferation and differentiation, and CSF1 produced by colon cancer cells contributes to the recruitment and infiltration of TAMs. In turn, IL-8 produced by TAMs can activate the PKC pathway on which CSF1 production depends (74).

Epithelial-mesenchymal transition (EMT) is an important development process that is activated during tumor cell migration and invasion (75). Activation of EMT prompts colon tumor cells to lose cell polarity and intercellular adhesion, and to acquire a mesenchymal appearance and greater infiltration and migration capabilities (76). In TME, several EMT-associated transcription factors (ZEB, SNAIL, and TWIST) synergize with signaling pathways in tumor cells (77–79) to induce EMT in response to stimulation by TGF-β, WNT, NOTCH, hypoxia (80–82), etc. TAMs have been demonstrated to have a key role in EMT in colon cancer. M2 macrophages overexpress MMP2 and MMP9, which can induce EMT (83). TGF-β is an important factor in EMT (84). M2 macrophages secrete a large amount of TGF-β, which promotes the expression of mesenchymal marker proteins (Vimentin) and reduces the expression of epithelial marker proteins (E-cadherin) during EMT in colon cancer cells (85). In addition, Wei et al. reported that TAM-derived IL-6 induced the EMT program by regulating the JAK2/STAT3/miR-506-3p/FoxQ1 axis to promote colon cancer cell invasion and migration (86). In colorectal cancer, the number of infiltrating TAMs is positively correlated with the expression of the activating transcription factor SANIL in cancer cells (76). TAMs also promote tumor invasion by up-regulating the expression of S100A8 and S100A9 in cancer cells (87).

Structural support for tumor development is provided by the ECM, including its main components collagen, glycoproteins and proteoglycans (88–90). Afik et al. found that in an orthotopic colorectal cancer model, TAMs promote the deposition, cross-linking, and linearization of collagen fibers to remodel tumor ECM composition and structure and promote tumor development (91).

Colon cancer cells can also activate matrix degradation-related signals to induce TAMs to produce tissue proteases, MMPs and serine proteases, etc., to promote ECM degradation and accelerate the invasion and migration of colon cancer cells (76, 88) (Figure 1B).

3.2 Mediation of angiogenesis and metastasis

Tumor growth and metastasis require increased intratumoral blood supply, which is usually triggered by tumor hypoxia (92). TAMs infiltrating the TME of colon tumors express HIF1α as an “angiogenic switch”, and respond to hypoxia signals by producing pro-angiogenic cytokines and growth factors, such as Angiopoietin-2 (Ang-2), VEGF, IL-8, CXCL1, and Fibroblast growth factor 2 (FGF-2), to induce endothelial cell recruitment, proliferation, and maturation, forming new blood vessels to promote tumor growth (67, 93, 94). GPR35 on macrophages in colon cancer promotes new angiogenesis and increases MMPs activity through Na/K-ATPase-dependent ion pumps and Src activation (94). Additionally, multiple studies have shown that the number of TAMs in colon cancer correlates with vascular density and the number of lymphatic vessels (95–97). Macrophages on blood vessels emit attractive signals that assist colon cancer cells in migrating along collagen fibers toward the vessels, enabling their escape into the bloodstream. TAMs can also activate the EGFC/VEGFR3 axis, which supports primary colorectal cancer cells growth and metastasis by shaping the lymphatic vessels and providing a pathway for tumor cells to invade the lymphatic system (98) (Figure 1C).

3.3 Establishment of immunosuppressive microenvironment

During colon cancer progression, the body’s anti-tumor immunity is suppressed, and tumor cells effectively evade anti-tumor immunity by deriving a tumor-immunosuppressive microenvironment, which involves inducing deletion or functional impairment of tumor-reactive T-cells (99) and recruiting immunosuppressive cell populations such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) (100). TAMs participate in and regulate the tumor immunosuppressive microenvironment by secreting cytokines and altering their phenotype (predominantly M2 macrophages) (101).

TAMs exert immunosuppressive functions through the secretion of inhibitory factors, such as IL-10, TGF-β, and Indoleamine 2,3-Dioxygenase 1 (IDO1) (68, 102), some enzymes, such as COX2, Arginase 1 (ARG1), Inducible nitric oxide synthase (INOS), and MMPs (101), as well as the release of chemokines (e.g., CCL2, CCL3, CCL4, CCL5, and CCL20) (68, 103, 104). The release of these factors not only directly inhibits the activity of T cells (105), but also promotes the recruitment of Tregs and MDSCs in the TME. For example, TAMs promote the aggregation of CCR6+ Treg cells by secreting CCL20 (106), and secreted CCL5 inhibits the killing of HT29 cells by T cells by stabilizing PD-L1, which in turn promotes immune escape (107). In tissue samples from colon cancer patients, the number of Treg cells and macrophages was significantly higher in cancerous tissues than in precancerous tissues (108). The infiltration of a large number of M2 macrophages is associated with poor prognosis, while the infiltration of CD8+ T cells is associated with improved patient survival (109). It was found that cytotoxic T cell responses could be enhanced to prevent colon cancer metastasis by inhibiting TGF-β produced by M2 macrophages (110). In addition, infiltration of high-density CXCR6⁺ TAMs promote the overexpression of IL-6, which would inhibit the activation of CD8⁺ T cells, thus contributing to immunosuppression (111). Ding et al. demonstrated that targeted inhibition of MDSCs could improve the immune microenvironment of colon cancer, not only promoting the maturation of dendritic cells and tumor infiltration of CD8⁺ T cells, but also reducing the number of Tregs and M2 macrophages (112) (Figure 1D).

3.4 Phagocytosis checkpoints and tumor immune evasion

Macrophages, as “professional” phagocytes in the innate immune system, play the role of scavengers. However, to evade clearance, tumor cells usually overexpress anti-phagocytic membrane proteins with “don’t eat me” signals, such as CD47, CD24, MHC-I, and PD-L1. These antiphagocytic proteins may interact with receptors on macrophages (e.g., SIRPα, Siglec-10, LILRB1, and PD-1) to evade phagocytosis. The anti-phagocytic signals generated by these binding are known as “Phagocytosis checkpoints”. Targeting phagocytosis checkpoints such as CD47-SIRPα, CD24-Siglec-10, MHC-LILRB1, PD1-PDL1 and thereby modulating immune escape in colon cancer cells has also been demonstrated.

Studies have found that using blocking antibodies targeting CD47 overexpressed on colon cancer cells and SIRPα on TAMs can inhibit the migration of colon cancer cells (113–115). In addition, phagocytic activity of macrophages was enhanced after anti-SIRPα antibody treatment (116). Interestingly, under hypoxic conditions, TAMs showed decreased SIRPα expression accompanied by increased phagocytic activity, whereas colon cancer cells showed elevated expression of CD47 and exhibited greater invasiveness (117). Therefore, it can be hypothesized that the regulation of the CD47-SIRPα axis in colon cancer may be affected by hypoxia.

CD24 serves as a critical “don’t eat me” signal molecule expressed by tumor cells. Several studies have indicated that its overexpression in colorectal cancer cells is associated with early-stage tumor metastasis (118). In colon cancer xenograft mouse models, treatment with anti-CD24 antibodies effectively suppressed the tumor growth (119, 120). Interestingly, Nersisyan et al. reported that reduced CD24 expression or gene loss in colon cancer patients was linked to shorter overall survival (121). These findings suggest that CD24 may function as a stage-specific driver during colorectal tumorigenesis—upregulated in early disease and potentially regulated later by shifts in immune cell activity. Zhao et al. further found a negative correlation between CD24 expression and multiple immune-related pathways, including TNF-α, NF-κB, and IFN-γ signaling (122). Siglec-10 has also been identified as an early driver gene in colorectal malignancies, with mutations observed in both multiple colonic adenomas and colorectal tumors (123). Single-cell RNA sequencing data revealed an enrichment of FOLR2⁺ LYVE1⁺ macrophages in KRAS/TP53 double-mutant colon cancer, where tumor cells appear to engage in immunosuppressive crosstalk with macrophages via the CD24–Siglec-10 axis. (124). Blocking the CD24–Siglec-10 anti-phagocytic axis effectively activates macrophage-mediated phagocytosis in the MC38 colon cancer model (125).

In colorectal cancer DLD1 cells, MHC-I expression suppresses macrophage-mediated phagocytosis and promotes immune evasion, primarily through its interaction with LILRB1 on TAMs. In vivo studies have shown that CRISPR-mediated knockout of MHC-I molecules in tumor cells suppresses tumor growth in a macrophage-dependent manner (126). However, in tumor tissues from patients with colon cancer liver metastases, high expression of MHC-I (β2m) on tumor cells has been associated with improved overall survival and increased T cell infiltration (126). The dual role of MHC-I in tumor immune evasion may stem from its capacity to engage both innate and adaptive immune responses. When functioning as an antigen-presenting molecule to cytotoxic T lymphocytes, MHC-I may no longer interact effectively with LILRB1. Additionally, some studies have reported that reduced MHC expression on tumor cell surfaces impairs antigen presentation, which may, in turn, enhance macrophage-mediated phagocytosis (127).

PD-1/PD-L1 inhibitors have been shown to effectively reverse T cell immune tolerance. In addition to T cells, PD-1 is also expressed on other immune cells, including macrophages, B cells, NK cells, and dendritic cells. Notably, increasing attention has been directed toward the functional role of PD-1/PD-L1 signaling in TAMs (128). Studies have reported that colon cancers with MSI-H tend to exhibit elevated PD-L1 expression, and that PD-1 levels on TAMs increase as the disease progresses (14, 129). PD-1 expression on macrophages has been implicated in promoting polarization toward the immunosuppressive M2 phenotype. In murine models of colorectal cancer, PD-1 blockade has been shown to reduce the infiltration of M2 macrophages within the TME (130). The PD-1/PD-L1 axis is considered part of an anti-phagocytic signaling pathway. In both colon cancer patients and mouse models, high PD-1 expression on TAMs has been associated with reduced phagocytic activity against tumor cells. Disruption of this axis can induce M1 polarization of macrophages and promote CD8⁺ T cell activation, thereby enhancing antitumor immunity (14). (Figure 1D).

3.5 The metabolic plasticity of TAMs

In pro-inflammatory or anti-inflammatory TME, TAMs exhibit notable metabolic plasticity. They comprehensively reprogram their energy sources, metabolic pathways, and metabolites to adapt to tumor progression. In colon cancer, tumor cells undergoing rapid proliferation produce lactate through the Warburg effect. The resulting acidic environment facilitates TAM recruitment and induces their immunosuppressive functions.

Similar to tumor cells, M1 macrophages rely on aerobic glycolysis and the pentose phosphate pathway (PPP), with upregulation of HIF-1α-related signaling, promoting the production of lactate and succinate (131). In contrast, M2 macrophages exhibit lower glucose consumption and primarily depend on fatty acid oxidation (FAO) and oxidative phosphorylation (OXPHOS) for energy supply. They express high levels of CD36, facilitating fatty acid uptake and β-oxidation. Additionally, FAO-induced mitochondrial stress and elevated ROS levels contribute to M2 polarization (132). It has been shown that the STING agonist GB2 can induce metabolic reprogramming of TAMs in colorectal cancer by upregulating the glycolysis–ROS–HIF-1α axis and downregulating OXPHOS, thereby promoting M1 polarization and enhancing phagocytic activity (133).

Increased glucose uptake leads to the accumulation of lactate in the TME. Zhang et al. were the first to reveal the role of histone lysine lactylation in the modification of macrophages, demonstrating that the level of lysine lactylation is positively correlated with intracellular lactate concentration (54). In colon cancer, elevated lactate levels promote M2 polarization and the secretion of signaling molecules that facilitate tumor progression. (76, 133). For example, lactate in the tumor microenvironment epigenetically upregulates the expression of VSIG4 in macrophages, which subsequently activates the JAK2/STAT3 pathway, enhances fatty acid oxidation and PPAR-γ expression, and drives polarization toward an immunosuppressive M2 phenotype (134).

In terms of amino acid metabolism, M1 macrophages primarily utilize arginine metabolism by upregulating iNOS to produce citrulline and NO, thereby enhancing antimicrobial and antitumor activity. In contrast, M2 macrophages upregulate ARG1, converting arginine into ornithine and polyamines, which contribute to immunosuppression (16). Increased expression of ARG1 has been identified as a key factor in rapid tumor growth and progression (16). Additionally, M2 macrophages metabolize tryptophan via IDO1 to generate kynurenine, which suppresses T cell function and promotes immune tolerance. It has been shown that inhibiting ARG1 while activating iNOS can effectively increase the number of M1 macrophages and suppress colon tumor growth (135).

3.6 Exosomal crosstalk with colon cancer cells

Autocrine and paracrine signaling mediated by cytokines and chemokines plays a pivotal role in the communication between tumor cells and TAMs. Both tumor cells and TAMs are capable of internalizing exosomes secreted by one another, thereby releasing their endosomal contents. This exchange contributes to the regulation of macrophage polarization and influences key tumor behaviors, including invasion, metastasis, and immune evasion (Table 2) (Figure 2).

Figure 2

In colon cancer, exosomes released by TAMs and colon cancer cells jointly contribute to the regulation of tumor immunity. Specifically, colon cancer cells can secrete exosomes containing various non-coding RNAs—including microRNAs (miRNAs), long non-coding RNAs, and circular RNAs, which influence TAM polarization. For instance, exosomal miR-1246 and miR-92a-3p derived from tumor cells have been shown to activate STAT3 and ERK signaling pathways in TAMs, promoting their polarization toward an immunosuppressive M2 phenotype (137, 149). Similarly, circ_0020095 facilitates tumor cell invasion and migration by downregulating IRAK1 expression and suppressing M1 polarization (139). In addition to RNA cargo, tumor-derived exosomes can also transport specific proteins that modulate the immune response. HSP90B1, delivered via exosomes from colorectal cancer cells, has been associated with poor prognosis in advanced colorectal cancer and contributes to liver metastasis by promoting the conversion of M1 to M2 macrophages (141). Notably, treatment targeting HSP70-positive exosomes produced by colorectal cancer cells has been reported to enhance antitumor immune responses, suggesting that TAMs possess functional plasticity (142).

On the other hand, TAMs can also influence tumor progression through the transfer of RNA and protein molecules encapsulated within exosomes. For example, M2 macrophages have been shown to promote colon cancer cell proliferation by delivering ferritin heavy chain (FTH1) protein via exosomes (148). Additionally, TAM-derived exosomes exhibit high levels of miR-21-5p and miR-155-5p, which target and suppress the expression of BRG1 in tumor cells, thereby enhancing their malignant properties and facilitating immune evasion (143).

3.7 Interaction with gut microbiota

Evidence suggests that chronic low-grade inflammation due to gut microbial dysbiosis as well as impaired intestinal barriers are important factors driving colon cancer development (150–152). Infiltrating bacterial products can construct an immunosuppressive TME by shaping TAMs (153). Fewer macrophages were found in the intestinal wall of germ-free mice compared to SPF mice (154, 155). Enrichment of Fusobacterium nucleatum, Bacteroides fragilis, Escherichia coli, and Enterococcus faecalis has been observed in the feces or tumor tissues of colorectal cancer patients (156–159). The establishment of chronic inflammation promotes colorectal cancer development. In APCmin/+ mice, Fusobacterium nucleatum facilitates the recruitment and infiltration of specific myeloid cell subsets into tumor tissue, producing NF-kB-related pro-inflammatory characteristics (160, 161). In a mouse model infected with Citrobacter rodentium, macrophage-derived ornithine decarboxylase promotes M1 macrophages activation, leading to increased mucosal inflammation in the colon (162). Gut microbes also promote colon carcinogenesis by modulating macrophage immunoreactivity. In Fusobacterium nucleatum-fed mouse models with intestinal tumors, M2-like macrophage accumulation has been observed within tumor tissues, showing significant suppressive activity against CD4+ T cells (160). Additionally, bacterial products such as muramyl peptides activate NOD1, maintaining ARG-1 overexpression and promoting colorectal tumor formation by modulating the immunosuppressive activity of MDSCs and TAMs (153). However, most current studies have focused on the crosstalk between tumorigenic bacteria and TAMs, and the role of some beneficial bacterial species is easily overlooked. For example, Akkermansia muciniphila, a probiotic with strong adhesion to the intestinal epithelial cell surface, can mediate M1 macrophages accumulation in a TLR2/NLRP3-dependent manner to inhibit colorectal tumorigenesis (163) (Figure 1E).

4 Therapeutic strategies targeting TAMs in colon cancer

Historically, natural products have provided many active molecules with novel structures for new drug development. Many anticancer compounds derived from natural products or their derivatives, such as paclitaxel and vincristine, have played an important role in the clinical treatment of cancer. Recent preclinical studies have further confirmed that natural products can effectively prevent and treat colon cancer by targeting TAMs. We summarize various natural products, including monomeric compounds, synthetic formulations based on natural products, combination therapies of natural products with existing anti-cancer drugs, nanoparticle-based drugs, traditional Chinese medicine, and dietary interventions. The primary mechanisms by which these natural products target TAMs include: inhibition of the inflammatory tumor microenvironment, regulation of macrophage polarization (such as inducing M1 polarization and suppressing M2 polarization) (Figure 3), modulation of metabolism, enhancement of macrophage phagocytic function, and modulation of other immune cells through TAMs, thereby effectively inhibiting immunosuppressive TME. These aspects will be discussed in detail in the following sections.

Figure 3

4.1 Botanical compounds and medicinal plants

Studies have confirmed that botanical compounds exhibit significant pharmacological and biological activities in the treatment of colon cancer (164, 165). Among these, polysaccharides, polyphenols, saponins, quinones, and terpenoids have been found to exert anti-tumor effects by modulating TAMs. The specific mechanisms of action are summarized in the table below (Table 3).

4.1.1 Polyphenols: remodeling immune microenvironment and inhibiting inflammation

Polyphenols are the most common plant-based bioactive constituents of the diet and are widely found in fruits, vegetables, cereals, coffee and green tea. Numerous experimental studies have demonstrated that polyphenols (e.g., procyanidins (166), curcumin (167), piceatannol (168), luteolin (169)) have significant anti-inflammatory, anti-tumor, pro-apoptotic, and immunomodulatory effects in colon cancer. Mechanistic studies indicate that these effects are primarily achieved through the regulation of TAM polarization, downregulation of inflammatory signaling, enhancement of immune responses, modulation of macrophage metabolism, and regulation of the gut microbiota. For example, single-cell sequencing analysis has shown that cannabidiol, a non-psychoactive compound from cannabis, promotes TAM glycolysis while inhibiting FAO and oxidative phosphorylation OXPHOS. It also regulates the PI3K/AKT pathway, promoting M1 polarization of TAMs to exert anti-colon cancer effects (170). Meanwhile, some polyphenol-rich extracts/non-extractable polyphenolic substances are also of interest. For example, polyphenol-rich components from edible seaweeds (171) and non-extractable phenolic from strawberries (172) were able to inhibit the pro-inflammatory activity of LPS-stimulated macrophages, induce cell cycle arrest in HCT116 human colon cancer cells, and promote their apoptosis.

4.1.2 Polysaccharides: activating M1 polarization and modulating signaling pathways

Natural polysaccharides have a wide range of biological activities, with anti-tumor, antioxidant, liver protection, immunomodulation and other functions. Because of their good therapeutic effects and mild adverse reactions, they have received extensive attention in the field of biomedicine. Many natural polysaccharides, such as fucoidan, safflower polysaccharides, cnidium officinale polysaccharides, and ganoderma lucidum polysaccharide, are effective in preventing and controlling colon cancer by regulating the signaling pathway, influencing the macrophage phenotype and function, enhancing immune response, and maintaining intestinal homeostasis.

Polysaccharides from algae have been extensively studied, for example, fucoidan extracted from brown algae activates the TLR4-mediated PI3K/AKT/mTOR signaling axis, promoting M1 polarization and infiltration of TAMs, thereby altering the immunosuppressive TME (175). Polysaccharides from Nostoc commune Vaucher can inhibit colon cancer cell proliferation by activating NF-κB, AKT/JNK1/2 signaling pathway, upregulating the expression of inflammatory factors, and enhancing the phagocytic activity of TAMs (176). Studies have shown that safflower polysaccharide (108), Cnidium officinale polysaccharide (178) and Beta-1,6 glucan (179) can activate the NF-κB and MAPK signaling pathways in colon cancer, promote the activation of M1 macrophages in the TME to generate immune responses. Shin et al. found that treatment of colon cancer model mice with the polysaccharides from ginseng leaves exhibited antitumor activity, and it promoted the secretion of TNF-α and IL-12 from macrophages in peritoneal exudates (181). Adenomatous polyps are considered precancerous lesions of sporadic colon cancer, and Ganoderma lucidum polysaccharide were effective in improving the inflammatory intestinal barrier in APCmin/+ mice reducing the formation of adenomatous polyps by decreasing the infiltration of inflammatory TAMs (180).

4.1.3 Saponins and terpenoids: modulation TAMs recruitment and suppressing M2 polarization

Studies on the regulation of TAMs in colon cancer by saponin compounds are mainly focused on ginsenosides. Ginsenosides have a variety of pharmacological activities and biological effects, such as anti-inflammatory, antioxidant, immunomodulatory, anti-tumor, and pro-apoptotic. Panaxynol, isolated from ginsenosides, promotes tumor cell apoptosis by effectively inhibiting M2 polarization in colon cancer TME (182). Furthermore, ginsenoside-Rp1 inhibits phenotypic variation in CT26 colon cancer cells by suppressing LPS-stimulated macrophage activation (183). Astragaloside IV (184) and jiaogulan saponins (180) extracted from traditional Chinese medicine, were able to reduce the formation of intestinal polyps and tumors by modulating the ratio of pro-inflammatory to anti-inflammatory macrophages in the TME.

From the current reports, it has been found that terpenoids improve colon cancer outcomes by interfering with TAMs including 1) prevention of colon precancerous lesions, 2) inhibition of tumor cell recruitment, proliferation, migration, and angiogenesis, 3) promotion of apoptosis, and 4) activation of immune response. Copaifera reticulata Ducke oleoresin, widely used in Brazilian folk medicine, has wound healing-promoting and anti-inflammatory effects. Its main chemical component, diterpene ent-polyalthic acid, reduces DNA damage and preneoplastic lesions induced by the carcinogen, also reduces NO and PGE2 production in mouse TAMs, demonstrating the potential for preventing the development of colon cancer (185). Dihydroisotanshinone I, a bioactive compound in Salvia miltiorrhiza Bunge can hinder the recruitment of TAMs to colon cancer cells by inhibiting the secretion of CCL2 from TAMs (186). Jiang et al. found that tretinoin inhibited NF-κB and ERK1/2 signaling and reduced M2 macrophage polarization remodeling TME by downregulating CXCL12 expression (187). Oridonin has excellent anti-angiogenic effects in colon cancer, reduces M2 macrophage infiltration, and also improves the hypoxic environment (188).

4.1.4 Quinones: inducing immunogenic cell death

Quinones are widely distributed in nature and are categorized into four major subclasses, including benzoquinone, naphthoquinone, phenanthrenequinone and anthraquinone. There are limited reports on whether quinones can prevent colon cancer by affecting TAMs, which have only been reported in Bullatacin. Emodin is a naturally occurring anthraquinone compound isolated from herbs such as rhubarb, Tigen stick as well as Tuber Fleeceflower Root, and has a variety of biological activities including anti-inflammatory, antioxidant, and antitumor. Studies have confirmed the role of Emodin in regulating colonic TME, not only by decreasing the proportion of M2 macrophages, but also by reducing inflammatory activation through inhibition of the P2X7 receptor (191). Bullatacin, a natural quinone compound isolated from the plant Lycopersiconaceae, induces immunogenic cell death (ICD) in tumor cells. Fan et al. demonstrated that treatment with Bullatacin promotes the accumulation of the “eat me” signaling proteins, CRT and HSP90, on the surface of colorectal tumor cells. It triggers ICD by activating the endoplasmic reticulum stress (ERS) signaling pathway and promotes phagocytosis of tumor cells by macrophages (192).

4.2 Natural product–based synthetic agents

Natural compounds face limitations in clinical applications, such as unstable efficacy, poor solubility, and challenges in standardization. To overcome these issues, synthetic modifications can be employed to create novel drug formulations by knocking out or altering certain unstable structures of the compounds. We summarize the role and mechanisms of existing synthetic formulations based on natural products targeting TAMs in colon cancer (Table 4).

Aspirin, derived from salicylic acid, is a classic non-steroidal anti-inflammatory drug. Long-term low-dose administration of aspirin (25 mg/kg daily in healthy mice, equivalent to 100 mg in human subjects) significantly reduces macrophage infiltration in colon tumors, shrinks tumor size, and decreases the formation of prostaglandin E2 (PGE2) in the colon (193).Modified mannose β-cyclodextrin (Man-MβCD) can be recognized by mannose receptors (MR) on TAMs, enhancing the cytotoxic activity of M2 macrophages while promoting tumor cell autophagy (196).Plinabulin, a microtubule inhibitor synthesized from a natural product isolated from marine Fusarium fungi through structural optimization, is undergoing global Phase III clinical trials for tumor treatment. In vivo studies have shown that Plinabulin (7 mg/kg) induces M1 polarization in macrophages through the JNK signaling pathway, effectively inhibiting tumor growth in MC38 colon cancer-bearing mice (195).The synthetic retinoid derivative fenretinide demonstrates advantages in chemoprevention, significantly reducing tumor occurrence in APCmin/+ mice by inhibiting STAT6 signaling and decreasing M2 macrophage-driven angiogenesis in tumor tissues (194).Blocking CSF-1/CSF-1R signaling to regulate TAM polarization is a promising therapeutic approach. A synthesized compound 21 from a series of (Z)-1-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)-3-(isoxazol-3-yl)urea derivatives exhibits excellent CSF-1R inhibitory activity (IC50 = 2.1nM), promoting M1 macrophage infiltration and enhancing anti-tumor immune responses (197).

While synthetic formulations effectively improve the efficacy and stability of natural products, the high research and development costs, along with complex clinical trial processes, remain significant obstacles to their widespread application. Improving the production methods of synthetic formulations, such as utilizing advanced techniques like computer-aided drug design, can aid in the development of synthetic formulations based on natural products.

4.3 Combination therapy: immune checkpoint inhibitors and multitarget synergy

Currently, immune checkpoint inhibitors (ICIs, immune checkpoint inhibitors) are working in microsatellite instable/mismatch repair deficient patients that account for about 5-10% of CRC cases. Optimized combination therapy strategies could expand the use of anti-PD-1/PD-L1-based immunotherapy in colon cancer. Although current immunotherapies are mostly centered on T cells, more and more reports support that the effector function of innate immunity is also important for cancer treatment (Table 4).

Several studies have explored the synergistic effects of natural products combined with anti-PD-1 (aPD-1) immunotherapy in colon cancer, primarily through the inhibition of TAMs’ M2 polarization and the activation of T-cell immune responses. For example, Astragaloside IV (AS-IV) from Astragalus membranaceus, sesquiterpene lactones from Arctium lappa, and the natural Chinese yam polysaccharide (CYP) have been shown to shift TAMs from the immune-suppressive M2 phenotype to the anti-tumor M1 phenotype. When used in combination with aPD-1, these natural products enhance the tumor immune response, increase the infiltration of CD8+ T cells, and inhibit tumor growth (184, 198, 200). Additionally, CYP has been found to effectively regulate the disruption of gut microbiota and metabolic products associated with aPD-1 treatment (200).

Another promising strategy involves combining natural compounds with conventional chemotherapy agents such as 5-FU. While 5-FU is a cornerstone in the treatment of colon cancer, its efficacy is limited due to the development of chemoresistance. 7S,15R-Dihydroxy-16S,17S-Epoxy-Docosapentaenoic Acid (diHEP-DPA), a DHA derivative, has been shown to overcome 5-FU resistance when used in combination, inhibiting TAM infiltration, reducing the accumulation of cancer stem cells (CSCs), and suppressing EMT (201, 202). Similarly, Ovatodiolide enhances anti-tumor effects when combined with 5-FU by inhibiting the YAP1 oncogenic pathway and preventing M2 TAM polarization (203).

The combination of natural products with existing cancer therapies (such as ICIs and chemotherapy) offers multiple advantages, particularly in enhancing current therapeutic efficacy, overcoming resistance, and reducing side effects. However, current research has primarily focused on the combination of natural products with anti-PD-1 immunotherapy, with limited studies on the use of other immunotherapies in combination with natural products for colon cancer treatment. Future research should explore the synergistic effects of different immune checkpoint inhibitors with natural products to provide more treatment options for clinical practice.

4.4 Nanomedicine strategies involving natural products

Nanomedicines have shown great potential in cancer treatment and have become a promising strategy to overcome the pharmacokinetic limitations of natural compounds. Despite substantial evidence supporting the superior antitumor effects of natural products, their clinical application remains limited due to issues such as poor solubility, low bioavailability, and insufficient systemic stability. The rapid development of functional nanomaterials has enabled nanomedicines to effectively address these challenges by facilitating accurate drug release, enhancing tumor penetration, and improving retention through the enhanced permeability and retention (EPR) effect, all while reducing toxicity and side effects (204). Common carriers include biomimetic delivery platforms (e.g., erythrocyte membranes, leukocyte membranes, stem cell membranes, and extracellular vesicles), liposomes, polymeric particles, and inorganic nanoparticles. Preclinical studies suggest that TAM-targeting nanomedicines exhibit good safety, enhanced stability, and improved anticancer performance in colon cancer treatment (Table 5).

4.4.1 Biomimetic delivery systems

Cell membrane-coated nanoparticles, which mimic the structure of cell membranes, can enhance biocompatibility and improve drug targeting. For example, erythrocyte membrane-coated nanoparticles (RSV-NPs@RBCm) effectively evade macrophage phagocytosis, extend the circulation time of drugs in the bloodstream, and improve tumor-targeted delivery through tumor-penetrating peptides (205). Extracellular vesicle-like nanoparticles derived from fresh ginseng can inhibit M2 polarization, modulating arginine metabolism to affect the mTOR-T-bet axis, thereby effectively alleviating T cell exhaustion (207). Furthermore, macrophage-derived extracellular vesicle nanoparticles possess excellent biocompatibility, enabling efficient drug loading and inhibition of colorectal cancer cell proliferation, migration, and resistance (208).

4.4.2 Liposomes

Liposomes, due to their excellent biocompatibility and biodegradability, are widely used as classic nanocarriers. Their structure consists of an outer lipid bilayer and an internal hydrophilic core. For example, saffron extract-loaded liposomes modified with M2 peptides specifically target M2 macrophages in the colorectal TME, inducing their polarization to the M1 phenotype, thereby exerting antitumor effects (211). Additionally, tocopheryl succinate succinate nanoparticles synthesized with egg phosphatidylcholine prevent peritoneal dissemination caused by colon cancer through intraperitoneal injection. This mechanism may involve the suppression of M2 macrophages, reducing the release of IL-10 and VEGF, and improving the TME (213).

4.4.3 Inorganic nanomaterials

Inorganic nanomaterials, such as metal nanoparticles, metal oxides, and carbon-based nanomaterials, are widely utilized in tumor therapy due to their biological stability and targeting capabilities. For instance, CaZCH NPs, which respond to the acidic conditions of the tumor microenvironment, release active substances that promote the infiltration of M1 macrophages and enhance antitumor immune responses by inducing ICD (209).

4.4.4 Polymeric nanomaterials

Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable and controlled-release drug delivery system approved by the FDA for sustained drug formulations. Natural product-based formulations, such as Apt-2cNP and CHO-PLGA-RA NPs, utilize PLGA as a carrier to modulate TAM polarization within the colorectal TME, inhibiting the NF-κB/STAT3 signaling pathway associated with M2 polarization and reshaping the immunosuppressive microenvironment (214, 215). Moreover, EBNPs avoid macrophage phagocytosis, effectively promoting cancer cell uptake, and achieving targeted inhibition of colon cancer cells (216).

Studies show that macrophage-targeting nanomedicines based on natural products have significant advantages. However, challenges remain, including instability in distribution, inter-individual variations in the EPR effect, and off-target effects. Furthermore, the heterogeneity of TAMs (including different subtypes, such as resident vs. recruited, anti-inflammatory vs. pro-inflammatory) influences therapeutic outcomes. The pharmacokinetic interactions between nanomedicines, tumor cells, and macrophages require further investigation. Additionally, animal models cannot fully replicate the complexity of the human tumor microenvironment. Future research should focus on improving the selective delivery of nanoparticles, reducing off-target toxicity, and enhancing therapeutic outcomes through more accurate pharmacokinetic modeling. Furthermore, in-depth studies on TAM heterogeneity and strategies for targeting different TAM subtypes will contribute to advancing the clinical application of nanomedicines.

4.5 Traditional Chinese medicine formulas: multitarget synergistic antitumor effects

Traditional Chinese medicines effectively inhibit the development of colon cancer through various pathways, such as enhancing immune response and inhibiting tumor proliferation and metastasis. Garcinia yunnanensis, a traditional Chinese medicine, has anticancer and anti-inflammatory effects, and after Garcinia yunnanensis treatment of APCmin/+ colon cancer model mice, JNK, STAT3 and ERK signaling were inhibited, M2 macrophage infiltration in the TME was reduced, and the size of tumors was reduced (219). Yi-Yi-Fu-Zi-Bai-Jiang-San (YYFZBJS) is a commonly used traditional Chinese medicine formula for treating inflammatory diseases. YYFZBJS can alter the pro-tumor effects of M2 macrophages by inhibiting inflammation-related signaling pathways in colon cancer and delay the development of the disease by reshaping the gut microbiota (220). Si-Jun-Zi Decoction (SJZ) is a well-known Chinese herbal formula that can regulate human immunity. After 3 weeks of treatment with full dose (45 g/kg) of modified SJZ in mice with colorectal cancer, the expression level of GM-CSF in plasma and the number of splenic macrophages were significantly increased, and the nude mice had better body defenses and colorectal cancer survival rate, and the modified SJZ also reduced the hepatic metastasis of colorectal cancer by activating the innate immunity (221).

The development of malignant tumors can have a deleterious effect on the patient’s mood and even accelerate tumor metastasis, and some traditional Chinese medicines can slow down this process. Xiao-Yao-San, is widely used clinically for the relief of symptoms associated with depression. Treatment of colorectal model mice with Xiao-Yao-San reduced the recruitment of M2 macrophages and MDSCs, and inhibited the expression of TGF-β, IL-6, MMP-9 and VEGF. Not only that, Xiao-Yao-San can also effectively inhibit liver metastasis of chronic stress colon tumors (222). Hereby, the natural products, with their excellent activity, safety and novel structures, offer more possibilities for the development of novel anti-colon cancer drugs.

4.6 Probiotics and gut microbiome regulation

Probiotics are defined by the World Health Organization (WHO) as “active microorganisms that, when ingested in sufficient quantities, are beneficial to the health of the host”. Probiotics stabilize the intestinal barrier and modulate intestinal immunity. Extensive research has shown that the consumption of probiotics (e.g. Lactobacillus plantarum, Lactobacillus acidophilus, and Bacillus subtilis) can alter the distribution of cellular junctional proteins, reduce the absorption of potentially cancer-causing compounds, and improve the poor prognosis of colon cancer (223–226).

lactobacilli, a probiotic used with high frequency in the treatment of diseases. Hradicka et al. found that Lactobacillus has immunomodulatory activity, remodels macrophage polarization, and reduces colon tumor tissue volume and total tumor number (227). Lactobacillus acidophilus lysate in combination with CTLA-4 helps to enhance anti-tumor immune response in colon cancer mice by decreasing Treg and M2 macrophage infiltration, and increasing the number of CD8+ T cells in the TME (228). Saccharomyces cerevisiae (S. cerevisiae) is a conventional yeast used in food products and a probiotic that maintains intestinal homeostasis. Beta-glucan, a major component of the cell wall of S. cerevisiae, inhibits colon tumor activity by suppressing intestinal ecological dysregulation and activating macrophages (229). Loigolactobacillus coryniformis NA-3 induces NO, IL-6, TNF-α, and ROS production in colonic TAMs and significantly inhibits the proliferation of colonic tumor cells (230). Notably, appropriate dosage and sufficient intestinal residence time are crucial for probiotics to exert anticancer immune effects (231). In addition, several studies have confirmed that the use of probiotics can help alleviate gastrointestinal adverse reactions such as diarrhea and nausea caused by chemotherapeutic drugs and improve patients’ treatment tolerance (231–233).

4.7 Dietary intervention

Dietary intervention is an emerging strategy for disease prevention and treatment. A Western diet characterized by high intake of red meat and high fat has been shown to significantly increase the risk of colorectal cancer (234). In contrast, diets rich in dietary fiber have a protective effect on the gut, not only providing an energy source for gut microbes, but also helping to maintain gut homeostasis and barrier integrity. Compared to normal-diet colon cancer model mice, ketogenic diet induces oxidative stress within colon tumors, promotes conversion of M2 macrophages to M1-type, and downregulates MMP expression to inhibit colon tumor progression (235). In addition, some dietary intake can also alleviate colon cancer progression to some extent. Feeding a diet rich in Oleuropein-Rich Leaf Extract to colon cancer model rats abrogated the overexpression of iNOS in rat tumors and inhibited the pro-inflammatory behaviors of macrophages in rats with loaded tumors, suppressing tumor proliferation (190). 3-Hydroxybutyrate (3HB) has various utilities as an oral food supplement, such as energy supply, anti-inflammation, neuroprotection, and can be used to improve alcoholic fatty liver, osteoporosis, and Alzheimer’s disease. Li et al. found that 3HB could regulate colon TME, modulate the proportion of infiltrating macrophages, and reduce the level of MDSCs, as well as inhibit the NF-κB pathway that reduces inflammatory factor release (236). Sea cucumber, a marine animal rich in bioactive molecules, is a dietary nutrient with anti-inflammatory and antibacterial effects. Adding sea cucumber extract Frondanol A5 to the feed fed to APCmin/+mice significantly reduced the volume of colon tumors, increased the phagocytosis efficiency of mouse peritoneal macrophages, and provided prevention for intestinal tumorigenesis (237).

5 Challenges and future perspectives

In this review, we summarize the potential of targeted modulation of TAMs in colon cancer prevention, occurrence, metastasis and drug resistance. The main pathways include modulation of TAMs infiltration in TME, remodeling of TAMs polarization, modulation of key signaling pathways in TAMs, promotion of phagocytic activity of TAMs, and activation of immunomodulatory function of TAMs. Potential therapeutic strategies include drug treatments based on natural products and dietary interventions (Figure 4). Colon carcinogenesis is a heterogeneous process with a diverse array of somatic molecular alterations influenced by diet, environmental and microbial exposures, and host immunity. With the deepening of research on colon cancer and the emergence of new therapeutic modalities, especially targeted therapies and immunotherapies, coupled with increasing early interventions, colon cancer has made great progress in diagnosis and treatment. However, toxic side effects, drug resistance, off-target effects, high metastasis and recurrence rates resulting from treatment are still important factors threatening human health.

Figure 4

Based on the current challenges in colon cancer treatment, it is particularly important to improve efficacy and overcome drug resistance without exacerbating immune-related side effects. A growing body of findings suggests that targeting macrophages for colon cancer treatment is a promising therapeutic approach.

However, there are some unresolved issues in the current studies on macrophages in colon cancer, and despite the large number of studies supporting that macrophage infiltration is suggestive of a poor prognosis, there are still data supporting the opposite result, which may be related to the lack of clarity of macrophage markers as well as difficulty in identifying the phenotype. Due to the tumor heterogeneity and plasticity of macrophages, the mechanism of how to inhibit macrophages from being “educated” by TME to perform their scavenging role to phagocytose tumor cells needs to be explored in greater depth. Macrophages signaling pathways and key regulatory factors affecting macrophages in colon cancer also need to be further revealed.

We have summarized potential natural drugs for targeting TAMs in the treatment of colon cancer. These include botanical active compounds, natural product-based synthetic formulations, therapies combined with existing anticancer treatments (such as ICIs and chemotherapy), natural product-based nanomedicines, probiotics, traditional Chinese medicine, and dietary interventions. These therapeutic strategies have addressed issues such as single efficacy, off-target effects, and drug resistance to some extent. Compared with traditional chemotherapy drugs, natural products tend to have fewer adverse effects and toxicities. Additionally, some traditional medicines can inhibit the growth of colon tumors by improving the body’s stress response. However, there are several challenges regarding the clinical application of natural products. Many phytochemicals exhibit poor solubility, resulting in low bioavailability. The bioavailability of some natural compounds remains unclear, and their metabolic pathways and transformation processes in vivo are not fully understood. Although progress has been made in improving the drug delivery efficiency and bioavailability of natural product-based nanomedicines and synthetic formulations, most studies are still in the basic experimental stage, and sufficient clinical data to support widespread application is lacking.

Natural products targeting TAMs for colon cancer treatment show great potential. Future research should focus on addressing key issues such as solubility, delivery efficiency, and bioavailability of natural products, and conduct more clinical trials to verify their efficacy and safety. As cancer biology continues to advance, these challenges are expected to be overcome through further technological innovations and research, ultimately contributing to cancer treatment and human health.

References

• 1

  MorganEArnoldMGiniALorenzoniVCabasagCJLaversanneMet al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. (2023) 72:338–44. doi: 10.1136/gutjnl-2022-327736

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2

  BensonABVenookAPAl-HawaryMMArainMAChenYJCiomborKKet al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. (2021) 19:329–59. doi: 10.6004/jnccn.2021.0012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3

  MortonDSeymourMMagillLHandleyKGlasbeyJGlimeliusBet al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. (2023) 41:1541–52. doi: 10.1200/jco.22.00046

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4

  PanjetaAKaurKSharmaRVermaIPreetS. Human intestinal defensin 5 ameliorates the sensitization of colonic cancer cells to 5-fluorouracil. Arch Med Res. (2024) 55:102966. doi: 10.1016/j.arcmed.2024.102966

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5

  KasiPMBuddeGKrainockMAushevVNKoyen MalashevichAMalhotraMet al. Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer. J Immunother Cancer. (2022) 10(1):e003312. doi: 10.1136/jitc-2021-003312

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6

  ZhangXYangRWuTCaiXLiGYuKet al. Efficacy and safety of neoadjuvant monoimmunotherapy with PD-1 inhibitor for dMMR/MSI⁃H locally advanced colorectal cancer: A single-center real-world study. Front Immunol. (2022) 13:913483. doi: 10.3389/fimmu.2022.913483

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7

  BrahmerJRLacchettiCSchneiderBJAtkinsMBBrassilKJCaterinoJMet al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. (2018) 36:1714–68. doi: 10.1200/jco.2017.77.6385

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8

  OzawaSMiuraTTerashimaJHabanoW. Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review. Cancer Drug Resist. (2021) 4:946–64. doi: 10.20517/cdr.2021.82

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9

  ChenBWuLTangXWangTWangSYuHet al. Quercetin inhibits tumorigenesis of colorectal cancer through downregulation of hsa_circ_0006990. Front Pharmacol. (2022) 13:874696. doi: 10.3389/fphar.2022.874696

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10

  ChenYWangBYuanXLuYHuJGaoJet al. Vitexin prevents colitis-associated carcinogenesis in mice through regulating macrophage polarization. Phytomedicine. (2021) 83:153489. doi: 10.1016/j.phymed.2021.153489

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11

  LiYLuQXiaoRMaJTangYChenWet al. Synthesis and anti-tumor activity of nitrogen-containing derivatives of the natural product diphyllin. Eur J Med Chem. (2022) 243:114708. doi: 10.1016/j.ejmech.2022.114708

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12

  ChenSSaeedALiuQJiangQXuHXiaoGGet al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. (2023) 8:207. doi: 10.1038/s41392-023-01452-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13

  MantovaniAAllavenaPMarchesiFGarlandaC. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. (2022) 21:799–820. doi: 10.1038/s41573-022-00520-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14

  GordonSRMauteRLDulkenBWHutterGGeorgeBMMcCrackenMNet al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. (2017) 545:495–9. doi: 10.1038/nature22396

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15

  LiYZhouHLiuPLvDShiYTangBet al. SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis. J Clin Invest. (2023) 133(4):e162870. doi: 10.1172/jci162870

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16

  YurdagulAJr.SubramanianMWangXCrownSBIlkayevaORDarvilleLet al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab. (2020) 31:518–533.e510. doi: 10.1016/j.cmet.2020.01.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17

  GüllüNSmithJHerrmannPSteinU. MACC1-dependent antitumor effect of curcumin in colorectal cancer. Nutrients. (2022) 14(22):4792. doi: 10.3390/nu14224792

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18

  YuanWZhangJChenHZhuangYZhouHLiWet al. Natural compounds modulate the mechanism of action of tumour-associated macrophages against colorectal cancer: a review. J Cancer Res Clin Oncol. (2024) 150:502. doi: 10.1007/s00432-024-06022-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19

  CoxNPokrovskiiMVicarioRGeissmannF. Origins, biology, and diseases of tissue macrophages. Annu Rev Immunol. (2021) 39:313–44. doi: 10.1146/annurev-immunol-093019-111748

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20

  LocatiMCurtaleGMantovaniA. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. (2020) 15:123–47. doi: 10.1146/annurev-pathmechdis-012418-012718

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21

  Rodríguez-MoralesPFranklinRA. Macrophage phenotypes and functions: resolving inflammation and restoring homeostasis. Trends Immunol. (2023) 44:986–98. doi: 10.1016/j.it.2023.10.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22

  OrecchioniMGhoshehYPramodABLeyK. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages. Front Immunol. (2019) 10:1084. doi: 10.3389/fimmu.2019.01084

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23

  ParkMDSilvinAGinhouxFMeradM. Macrophages in health and disease. Cell. (2022) 185:4259–79. doi: 10.1016/j.cell.2022.10.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24

  SheuKMHoffmannA. Functional hallmarks of healthy macrophage responses: their regulatory basis and disease relevance. Annu Rev Immunol. (2022) 40:295–321. doi: 10.1146/annurev-immunol-101320-031555

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25

  LazarovTJuarez-CarreñoSCoxNGeissmannF. Physiology and diseases of tissue-resident macrophages. Nature. (2023) 618:698–707. doi: 10.1038/s41586-023-06002-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26

  SicaAMantovaniA. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. (2012) 122:787–95. doi: 10.1172/jci59643

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27

  ToledoBZhu ChenLPaniagua-SanchoMMarchalJAPeránMGiovannettiE. Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy. J Hematol Oncol. (2024) 17:44. doi: 10.1186/s13045-024-01559-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28

  VarolCMildnerAJungS. Macrophages: development and tissue specialization. Annu Rev Immunol. (2015) 33:643–75. doi: 10.1146/annurev-immunol-032414-112220

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29

  MommertSGregorKRossbachKSchaperKWitteTGutzmerRet al. Histamine H2 receptor stimulation upregulates T(H)2 chemokine CCL17 production in human M2a macrophages. J Allergy Clin Immunol. (2018) 141:782–785.e785. doi: 10.1016/j.jaci.2017.06.023

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30

  PepeGCalderazziGDe MaglieMVillaAMVegetoE. Heterogeneous induction of microglia M2a phenotype by central administration of interleukin-4. J Neuroinflamm. (2014) 11:211. doi: 10.1186/s12974-014-0211-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31

  SezginerOUnverN. Dissection of pro-tumoral macrophage subtypes and immunosuppressive cells participating in M2 polarization. Inflamm Res. (2024) 73:1411–23. doi: 10.1007/s00011-024-01907-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32

  ZhangJLiYDuanZKangJChenKLiGet al. The effects of the M2a macrophage-induced axonal regeneration of neurons by arginase 1. Biosci Rep. (2020) 40(2):BSR20193031. doi: 10.1042/bsr20193031

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33

  AsaiANakamuraKKobayashiMHerndonDNSuzukiF. CCL1 released from M2b macrophages is essentially required for the maintenance of their properties. J Leukoc Biol. (2012) 92:859–67. doi: 10.1189/jlb.0212107

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34

  BianchiniRRoth-WalterFOhradanova-RepicAFlickerSHufnaglKFischerMBet al. IgG4 drives M2a macrophages to a regulatory M2b-like phenotype: potential implication in immune tolerance. Allergy. (2019) 74:483–94. doi: 10.1111/all.13635

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35

  YangCZhangDMSongZBHouYQBaoYLSunLGet al. Protumoral TSP50 regulates macrophage activities and polarization via production of TNF-α and IL-1β, and activation of the NF-κB signaling pathway. PLoS One. (2015) 10:e0145095. doi: 10.1371/journal.pone.0145095

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36

  JuniorLNguyenHTSalmanidaFPChangKT. MERTK(+/hi) M2c macrophages induced by baicalin alleviate non-alcoholic fatty liver disease. Int J Mol Sci. (2021) 22(19):10604. doi: 10.3390/ijms221910604

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37

  MikiSSuzukiJITakashimaMIshidaMKokuboHYoshizumiM. S-1-Propenylcysteine promotes IL-10-induced M2c macrophage polarization through prolonged activation of IL-10R/STAT3 signaling. Sci Rep. (2021) 11:22469. doi: 10.1038/s41598-021-01866-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38

  MokarramNMerchantAMukhatyarVPatelGBellamkondaRV. Effect of modulating macrophage phenotype on peripheral nerve repair. Biomaterials. (2012) 33:8793–801. doi: 10.1016/j.biomaterials.2012.08.050

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39

  TuGWShiYZhengYJJuMJHeHYMaGGet al. Glucocorticoid attenuates acute lung injury through induction of type 2 macrophage. J Transl Med. (2017) 15:181. doi: 10.1186/s12967-017-1284-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40

  BariloJRatsimorMChanAHembruffHBastaS. Polarized tissue-derived macrophages display enhanced M2d phenotype after prolonged stimulation with adenosine A(2A) receptor agonist in the presence of LPS. Front Biosci (Landmark Ed). (2025) 30:27638. doi: 10.31083/fbl27638

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41

  CaoWPetersJHNiemanDSharmaMWatsonTYuJ. Macrophage subtype predicts lymph node metastasis in oesophageal adenocarcinoma and promotes cancer cell invasion in vitro. Br J Cancer. (2015) 113:738–46. doi: 10.1038/bjc.2015.292

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42

  FerranteCJPinhal-EnfieldGElsonGCronsteinBNHaskoGOutramSet al. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Rα) signaling. Inflammation. (2013) 36:921–31. doi: 10.1007/s10753-013-9621-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43

  MurrayPJ. Macrophage polarization. Annu Rev Physiol. (2017) 79:541–66. doi: 10.1146/annurev-physiol-022516-034339

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44

  CarraraSCDavila-LezamaACabrielCBerenschotEJWKrolSGardeniersJGEet al. 3D topographies promote macrophage M2d-Subset differentiation. Mater Today Bio. (2024) 24:100897. doi: 10.1016/j.mtbio.2023.100897

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45

  LiuRHanCHuJZhangBLuoWLingF. Infiltration of apoptotic M2 macrophage subpopulation is negatively correlated with the immunotherapy response in colorectal cancer. Int J Mol Sci. (2022) 23(19):11014. doi: 10.3390/ijms231911014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46

  HastonSGonzalez-GualdaEMorsliSGeJReenVCalderwoodAet al. Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer. Cancer Cell. (2023) 41:1242–1260.e1246. doi: 10.1016/j.ccell.2023.05.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47

  VitaleIManicGCoussensLMKroemerGGalluzziL. Macrophages and metabolism in the tumor microenvironment. Cell Metab. (2019) 30:36–50. doi: 10.1016/j.cmet.2019.06.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 48

  NasirIMcGuinnessCPohARErnstMDarcyPKBrittKL. Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies. Trends Immunol. (2023) 44:971–85. doi: 10.1016/j.it.2023.10.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49

  PittJMMarabelleAEggermontASoriaJCKroemerGZitvogelL. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. (2016) 27:1482–92. doi: 10.1093/annonc/mdw168

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50

  CassettaLPollardJW. A timeline of tumour-associated macrophage biology. Nat Rev Cancer. (2023) 23:238–57. doi: 10.1038/s41568-022-00547-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 51

  MantovaniAMarchesiFMalesciALaghiLAllavenaP. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. (2017) 14:399–416. doi: 10.1038/nrclinonc.2016.217

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52

  ChenYZhangSWangQZhangX. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J Hematol Oncol. (2017) 10:36. doi: 10.1186/s13045-017-0408-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53

  BaiRLiYJianLYangYZhaoLWeiM. The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. Mol Cancer. (2022) 21:177. doi: 10.1186/s12943-022-01645-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54

  ZhangDTangZHuangHZhouGCuiCWengYet al. Metabolic regulation of gene expression by histone lactylation. Nature. (2019) 574:575–80. doi: 10.1038/s41586-019-1678-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 55

  DeligneCMurdamoothooDGammageANGschwandtnerMErneWLoustauTet al. Matrix-targeting immunotherapy controls tumor growth and spread by switching macrophage phenotype. Cancer Immunol Res. (2020) 8:368–82. doi: 10.1158/2326-6066.Cir-19-0276

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56

  MehlaKSinghPK. Metabolic regulation of macrophage polarization in cancer. Trends Cancer. (2019) 5:822–34. doi: 10.1016/j.trecan.2019.10.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57

  LiWChenFGaoHXuZZhouYWangSet al. Cytokine concentration in peripheral blood of patients with colorectal cancer. Front Immunol. (2023) 14:1175513. doi: 10.3389/fimmu.2023.1175513

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58

  WangHWangXZhangXXuW. The promising role of tumor-associated macrophages in the treatment of cancer. Drug Resist Update. (2024) 73:101041. doi: 10.1016/j.drup.2023.101041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59

  KhanduriIMaruDMParraER. Exploratory study of macrophage polarization and spatial distribution in colorectal cancer liver metastasis: a pilot study. Front Immunol. (2023) 14:1223864. doi: 10.3389/fimmu.2023.1223864

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60

  WangJZhuNSuXGaoYYangR. Novel tumor-associated macrophage populations and subpopulations by single cell RNA sequencing. Front Immunol. (2023) 14:1264774. doi: 10.3389/fimmu.2023.1264774

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61

  WuKLinKLiXYuanXXuPNiPet al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol. (2020) 11:1731. doi: 10.3389/fimmu.2020.01731

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 62

  GaoJLiangYWangL. Shaping polarization of tumor-associated macrophages in cancer immunotherapy. Front Immunol. (2022) 13:888713. doi: 10.3389/fimmu.2022.888713

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 63

  CavalleriTGrecoLRubbinoFHamadaTQuarantaMGrizziFet al. Tumor-associated macrophages and risk of recurrence in stage III colorectal cancer. J Pathol Clin Res. (2022) 8:307–12. doi: 10.1002/cjp2.267

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64

  ForssellJObergAHenrikssonMLStenlingRJungAPalmqvistR. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. (2007) 13:1472–9. doi: 10.1158/1078-0432.Ccr-06-2073

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65

  SchmittMGretenFR. The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol. (2021) 21:653–67. doi: 10.1038/s41577-021-00534-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 66

  De SimoneVFranzèERonchettiGColantoniAFantiniMCDi FuscoDet al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. (2015) 34:3493–503. doi: 10.1038/onc.2014.286

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 67

  Glaus GarzonJFPastrelloCJurisicaIHottigerMOWengerRHBorsigL. Tumor cell endogenous HIF-1α activity induces aberrant angiogenesis and interacts with TRAF6 pathway required for colorectal cancer development. Neoplasia. (2020) 22:745–58. doi: 10.1016/j.neo.2020.10.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 68

  JiaSNHanYBYangRYangZC. Chemokines in colon cancer progression. Semin Cancer Biol. (2022) 86:400–7. doi: 10.1016/j.semcancer.2022.02.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69

  ChoHSeoYLokeKMKimSWOhSMKimJHet al. Cancer-stimulated CAFs enhance monocyte differentiation and protumoral TAM activation via IL6 and GM-CSF secretion. Clin Cancer Res. (2018) 24:5407–21. doi: 10.1158/1078-0432.Ccr-18-0125

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70

  DoughertyUMustafiRSadiqFAlmoghrabiAMustafiDKreishehMet al. The renin-angiotensin system mediates EGF receptor-vitamin d receptor cross-talk in colitis-associated colon cancer. Clin Cancer Res. (2014) 20:5848–59. doi: 10.1158/1078-0432.Ccr-14-0209

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71

  LiCXuMMWangKAdlerAJVellaATZhouB. Macrophage polarization and meta-inflammation. Transl Res. (2018) 191:29–44. doi: 10.1016/j.trsl.2017.10.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72

  NandiBShapiroMSamurMKPaiCFrankNYYoonCet al. Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages. Oncoimmunology. (2016) 5:e1189052. doi: 10.1080/2162402x.2016.1189052

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 73

  YuJXuZGuoJYangKZhengJSunX. Tumor-associated macrophages (TAMs) depend on MMP1 for their cancer-promoting role. Cell Death Discov. (2021) 7:343. doi: 10.1038/s41420-021-00730-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 74

  WangHShaoQSunJMaCGaoWWangQet al. Interactions between colon cancer cells and tumor-infiltrated macrophages depending on cancer cell-derived colony stimulating factor 1. Oncoimmunology. (2016) 5:e1122157. doi: 10.1080/2162402x.2015.1122157

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75

  RigilloGBellutiSCampaniVRagazziniGRonzioMMiserocchiGet al. The NF-Y splicing signature controls hybrid EMT and ECM-related pathways to promote aggressiveness of colon cancer. Cancer Lett. (2023) 567:216262. doi: 10.1016/j.canlet.2023.216262

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 76

  WangLLiSLuoHLuQYuS. PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages. J Exp Clin Cancer Res. (2022) 41:303. doi: 10.1186/s13046-022-02477-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77

  GuanBLiHYaoJGuoJYuFLiGet al. CCL3-CCR5 axis promotes cell migration and invasion of colon adenocarcinoma via Akt signaling pathway. Environ Toxicol. (2023) 38:172–84. doi: 10.1002/tox.23675

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78

  HuXLiYQLiQGMaYLPengJJCaiSJ. Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway. J Exp Clin Cancer Res. (2018) 37:41. doi: 10.1186/s13046-018-0718-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 79

  ShenXHuXMaoJWuYLiuHShenJet al. The long noncoding RNA TUG1 is required for TGF-β/TWIST1/EMT-mediated metastasis in colorectal cancer cells. Cell Death Dis. (2020) 11:65. doi: 10.1038/s41419-020-2254-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80

  QuXZhaoLWangMZhangRChengLQiuLet al. Novel functional variants in the Notch pathway and survival of Chinese colorectal cancer. Int J Cancer. (2021) 149:84–96. doi: 10.1002/ijc.33561

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81

  VillarealLBFalconDMXieLXueX. Hypoxia-inducible factor 3α1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis. Br J Cancer. (2024) 130:1904–15. doi: 10.1038/s41416-024-02699-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82

  ZhaoHMingTTangSRenSYangHLiuMet al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer. (2022) 21:144. doi: 10.1186/s12943-022-01616-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 83

  VinnakotaKZhangYSelvanesanBCTopiGSalimTSand-DejmekJet al. M2-like macrophages induce colon cancer cell invasion via matrix metalloproteinases. J Cell Physiol. (2017) 232:3468–80. doi: 10.1002/jcp.25808

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 84

  SaitohM. Transcriptional regulation of EMT transcription factors in cancer. Semin Cancer Biol. (2023) 97:21–9. doi: 10.1016/j.semcancer.2023.10.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85

  LiSXuFZhangJWangLZhengYWuXet al. Tumor-associated macrophages remodeling EMT and predicting survival in colorectal carcinoma. Oncoimmunology. (2018) 7:e1380765. doi: 10.1080/2162402x.2017.1380765

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86

  WeiCYangCWangSShiDZhangCLinXet al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. (2019) 18:64. doi: 10.1186/s12943-019-0976-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87

  LimSYYuzhalinAEGordon-WeeksANMuschelRJ. Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. Oncogene. (2016) 35:5735–45. doi: 10.1038/onc.2016.107

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 88

  HornLAChariouPLGameiroSRQinHIidaMFousekKet al. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication. J Clin Invest. (2022) 132(8):e155148. doi: 10.1172/jci155148

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89

  LooJMScherlANguyenAManFYWeinbergEZengZet al. Extracellular metabolic energetics can promote cancer progression. Cell. (2015) 160:393–406. doi: 10.1016/j.cell.2014.12.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90

  YinYYangXChengZWangHLeiJWangDet al. Identification of extracellular matrix-related biomarkers in colon adenocarcinoma by bioinformatics and experimental validation. Front Immunol. (2024) 15:1371584. doi: 10.3389/fimmu.2024.1371584

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91

  AfikRZigmondEVugmanMKlepfishMShimshoniEPasmanik-ChorMet al. Tumor macrophages are pivotal constructors of tumor collagenous matrix. J Exp Med. (2016) 213:2315–31. doi: 10.1084/jem.20151193

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92

  LiangXChenMBhattaraiPHameedSDaiZ. Perfluorocarbon@Porphyrin nanoparticles for tumor hypoxia relief to enhance photodynamic therapy against liver metastasis of colon cancer. ACS Nano. (2020) 14:13569–83. doi: 10.1021/acsnano.0c05617

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93

  KorbeckiJBosiackiMBarczakKŁagockaRChlubekDBaranowska-BosiackaI. The clinical significance and role of CXCL1 chemokine in gastrointestinal cancers. Cells. (2023) 12(10):1406. doi: 10.3390/cells12101406

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94

  PaganoEEliasJESchneditzGSaveljevaSHollandLMBorrelliFet al. Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment. Gut. (2022) 71:509–20. doi: 10.1136/gutjnl-2020-323363

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95

  LiuXWangBLiYHuYLiXYuTet al. Powerful anticolon tumor effect of targeted gene immunotherapy using folate-modified nanoparticle delivery of CCL19 to activate the immune system. ACS Cent Sci. (2019) 5:277–89. doi: 10.1021/acscentsci.8b00688

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96

  TacconiCCorrealeCGandelliASpinelliADejanaED’AlessioSet al. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion. Gastroenterology. (2015) 148:1438–1451.e1438. doi: 10.1053/j.gastro.2015.03.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97

  WangLMaLSongZZhouLChenKWangXet al. Single-cell transcriptome analysis profiling lymphatic invasion-related TME in colorectal cancer. Sci Rep. (2024) 14:8911. doi: 10.1038/s41598-024-59656-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98

  TacconiCUngaroFCorrealeCArenaVMassiminoLDetmarMet al. Activation of the VEGFC/VEGFR3 pathway induces tumor immune escape in colorectal cancer. Cancer Res. (2019) 79:4196–210. doi: 10.1158/0008-5472.Can-18-3657

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99

  TrimaglioGTilkin-MariaméAFFeliuVLauzéral-VizcainoFTosoliniMValleCet al. Colon-specific immune microenvironment regulates cancer progression versus rejection. Oncoimmunology. (2020) 9:1790125. doi: 10.1080/2162402x.2020.1790125

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 100

  JiangLFeiHYangAZhuJSunJLiuXet al. Estrogen inhibits the growth of colon cancer in mice through reversing extracellular vesicle-mediated immunosuppressive tumor microenvironment. Cancer Lett. (2021) 520:332–43. doi: 10.1016/j.canlet.2021.08.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101

  LeeSJYangHKimWRLeeYSLeeWSKongSJet al. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. J Immunother Cancer. (2021) 9(6):e002195. doi: 10.1136/jitc-2020-002195

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102

  GhonimMAIbbaSVTarhuniAFErramiYLuuHHDeanMJet al. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer. J Immunother Cancer. (2021) 9(1):e001643. doi: 10.1136/jitc-2020-001643

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103

  AngellHKBruniDBarrettJCHerbstRGalonJ. The immunoscore: colon cancer and beyond. Clin Cancer Res. (2020) 26:332–9. doi: 10.1158/1078-0432.Ccr-18-1851

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 104

  KadomotoSIzumiKMizokamiA. The CCL20-CCR6 axis in cancer progression. Int J Mol Sci. (2020) 21(15):5186. doi: 10.3390/ijms21155186

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105

  JarnickiAGLysaghtJTodrykSMillsKH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. (2006) 177:896–904. doi: 10.4049/jimmunol.177.2.896

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 106

  LiuJZhangNLiQZhangWKeFLengQet al. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One. (2011) 6:e19495. doi: 10.1371/journal.pone.0019495

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107

  LiuCYaoZWangJZhangWYangYZhangYet al. Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway. Cell Death Differ. (2020) 27:1765–81. doi: 10.1038/s41418-019-0460-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 108

  WangJLiSLiHZhouXWenHLaiB. IRF4 overexpression promotes the transdifferentiation of tregs into macrophage-like cells to inhibit the development of colon cancer. Cancer Cell Int. (2021) 21:58. doi: 10.1186/s12935-021-01766-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 109

  MezheyeuskiAMickePMartín-BernabéABackmanMHrynchykIHammarströmKet al. The immune landscape of colorectal cancer. Cancers (Basel). (2021) 13(21):5545. doi: 10.3390/cancers13215545

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 110

  RosXRVermeulenL. Turning cold tumors hot by blocking TGF-β. Trends Cancer. (2018) 4:335–7. doi: 10.1016/j.trecan.2018.03.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111

  ChangJLinSMaoYXuYZhangZWuQet al. CXCR6+ Tumor-associated macrophages identify immunosuppressive colon cancer patients with poor prognosis but favorable response to adjuvant chemotherapy. Cancers (Basel). (2022) 14(19):4646. doi: 10.3390/cancers14194646

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 112

  DingDZhongHLiangRLanTZhuXHuangSet al. Multifunctional nanodrug mediates synergistic photodynamic therapy and MDSCs-targeting immunotherapy of colon cancer. Adv Sci (Weinh). (2021) 8:e2100712. doi: 10.1002/advs.202100712

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 113

  ChenCLiASunPXuJDuWZhangJet al. Efficiently restoring the tumoricidal immunity against resistant Malignancies via an immune nanomodulator. J Control Release. (2020) 324:574–85. doi: 10.1016/j.jconrel.2020.05.039

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 114

  OhHHParkYLParkSYMyungEImCMYuHJet al. CD47 mediates the progression of colorectal cancer by inducing tumor cell apoptosis and angiogenesis. Pathol Res Pract. (2022) 240:154220. doi: 10.1016/j.prp.2022.154220

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 115

  ZhangYSimeWJuhasMSjölanderA. Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. Eur J Cancer. (2013) 49:3320–34. doi: 10.1016/j.ejca.2013.06.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 116

  AbeTTanakaYPiaoJTanimineNOueNHinoiTet al. Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice. Ann Gastroenterol Surg. (2018) 2:451–62. doi: 10.1002/ags3.12205

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117

  MartinsFOliveiraRCavadasBPintoFCardosoAPCastroFet al. Hypoxia and macrophages act in concert towards a beneficial outcome in colon cancer. Cancers (Basel). (2020) 12(4):818. doi: 10.3390/cancers12040818

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 118

  ChoiDLeeHWHurKYKimJJParkGSJangSHet al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol. (2009) 15:2258–64. doi: 10.3748/wjg.15.2258

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119

  SagivEStarrARozovskiUKhosraviRAltevogtPWangTet al. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res. (2008) 68:2803–12. doi: 10.1158/0008-5472.Can-07-6463

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 120

  ShapiraSShapiraAStarrAKazanovDKrausSBenharIet al. An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice. Gastroenterology. (2011) 140:935–46. doi: 10.1053/j.gastro.2010.12.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 121

  NersisyanSAhlersAKLangeTWickleinDGalatenkoABohnenbergerHet al. Low expression of CD24 is associated with poor survival in colorectal cancer. Biochimie. (2022) 192:91–101. doi: 10.1016/j.biochi.2021.10.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122

  ZhaoCHuangYZhangHLiuH. CD24 affects the immunosuppressive effect of tumor-infiltrating cells and tumor resistance in a variety of cancers. Discov Oncol. (2024) 15:399. doi: 10.1007/s12672-024-01284-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123

  WolffRKHoffmanMDWolffECHerrickJSSakodaLCSamowitzWSet al. Mutation analysis of adenomas and carcinomas of the colon: Early and late drivers. Genes Chromosomes Cancer. (2018) 57:366–76. doi: 10.1002/gcc.22539

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 124

  LiuXXuXWuZShanQWangZWuZet al. Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers. Front Immunol. (2022) 13:961350. doi: 10.3389/fimmu.2022.961350

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 125

  ZhangYHeBZouPWuMWeiMXuCet al. Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors. J Immunother Cancer. (2025) 13(4):e010767. doi: 10.1136/jitc-2024-010767

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 126

  BarkalAAWeiskopfKKaoKSGordonSRRosentalBYiuYYet al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. (2018) 19:76–84. doi: 10.1038/s41590-017-0004-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 127

  ZhengNWangTLuoQLiuYYangJZhouYet al. M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance. Oncoimmunology. (2023) 12:2210959. doi: 10.1080/2162402x.2023.2210959

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128

  HutchinsonL. Immunotherapy: Exploiting PD-1 on TAMs for tumour cell kill. Nat Rev Clin Oncol. (2017) 14:392–3. doi: 10.1038/nrclinonc.2017.87

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 129

  ZhangYZengLWangMYangZZhangHGaoLet al. RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination. J Immunother Cancer. (2023) 11(9):e007313. doi: 10.1136/jitc-2023-007313

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 130

  DoleschelDHoffSKoletnikSRixAZopfDKiesslingFet al. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. J Exp Clin Cancer Res. (2021) 40:288. doi: 10.1186/s13046-021-02043-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 131

  ViolaAMunariFSánchez-RodríguezRScolaroTCastegnaA. The metabolic signature of macrophage responses. Front Immunol. (2019) 10:1462. doi: 10.3389/fimmu.2019.01462

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 132

  LiuYXuRGuHZhangEQuJCaoWet al. Metabolic reprogramming in macrophage responses. biomark Res. (2021) 9:1. doi: 10.1186/s40364-020-00251-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 133

  DengAFanRHaiYZhuangJZhangBLuXet al. A STING agonist prodrug reprograms tumor-associated macrophage to boost colorectal cancer immunotherapy. Theranostics. (2025) 15:277–99. doi: 10.7150/thno.101001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 134

  LiuJZhangWChenLWangXMaoXWuZet al. VSIG4 promotes tumour-associated macrophage M2 polarization and immune escape in colorectal cancer via fatty acid oxidation pathway. Clin Transl Med. (2025) 15:e70340. doi: 10.1002/ctm2.70340

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 135

  WangJDengSChengDGuJQinLMaoFet al. Engineered microparticles modulate arginine metabolism to repolarize tumor-associated macrophages for refractory colorectal cancer treatment. J Transl Med. (2024) 22:908. doi: 10.1186/s12967-024-05652-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136

  CooksTPaterasISJenkinsLMPatelKMRoblesAIMorrisJet al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat Commun. (2018) 9:771. doi: 10.1038/s41467-018-03224-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 137

  HuangYJHuangTHYadavVKSumitraMRTzengDTWeiPLet al. Preclinical investigation of ovatodiolide as a potential inhibitor of colon cancer stem cells via downregulating sphere-derived exosomal β-catenin/STAT3/miR-1246 cargoes. Am J Cancer Res. (2020) 10:2337–54.

  • Google Scholar

• 138

  ZhaoWWuYWangYLiTLiuQHouZ. Exosomal miR-92a-3p modulates M2 macrophage polarization in colorectal cancer: implications for tumor migration and angiogenesis. Med Oncol. (2025) 42:96. doi: 10.1007/s12032-025-02635-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 139

  HanYZhouZLiRWangH. Tumor-derived exosomal circ_0020095 promotes colon cancer cell proliferation and metastasis by inhibiting M1 macrophage polarization. J Biochem Mol Toxicol. (2025) 39:e70225. doi: 10.1002/jbt.70225

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 140

  GaoBWangLWenTXieXRuiXChenQ. Colon cancer-derived exosomal lncRNA-XIST promotes M2-like macrophage polarization by regulating PDGFRA. Int J Mol Sci. (2024) 25(21):11433. doi: 10.3390/ijms252111433

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 141

  LiSFuXNingDLiuQZhaoJChengQet al. Colon cancer exosome-associated HSP90B1 initiates pre-metastatic niche formation in the liver by polarizing M1 macrophage into M2 phenotype. Biol Direct. (2025) 20:52. doi: 10.1186/s13062-025-00623-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 142

  KomarovaEYSuezovRVNikotinaADAksenovNDGaraevaLAShtamTAet al. Hsp70-containing extracellular vesicles are capable of activating of adaptive immunity in models of mouse melanoma and colon carcinoma. Sci Rep. (2021) 11:21314. doi: 10.1038/s41598-021-00734-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 143

  LanJSunLXuFLiuLHuFSongDet al. M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer. Cancer Res. (2019) 79:146–58. doi: 10.1158/0008-5472.Can-18-0014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 144

  MaYSWuTMLingCCYuFZhangJCaoPSet al. M2 macrophage-derived exosomal microRNA-155-5p promotes the immune escape of colon cancer by downregulating ZC3H12B. Mol Ther Oncolytics. (2021) 20:484–98. doi: 10.1016/j.omto.2021.02.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 145

  ZhangSLiDZhaoMYangFSangCYanCet al. Exosomal miR-183-5p Shuttled by M2 Polarized Tumor-Associated Macrophage Promotes the Development of Colon Cancer via Targeting THEM4 Mediated PI3K/AKT and NF-κB Pathways. Front Oncol. (2021) 11:672684. doi: 10.3389/fonc.2021.672684

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146

  GuoJWangXGuoQZhuSLiPZhangSet al. M2 macrophage derived extracellular vesicle-mediated transfer of miR-186-5p promotes colon cancer progression by targeting DLC1. Int J Biol Sci. (2022) 18:1663–76. doi: 10.7150/ijbs.69405

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 147

  DingYZhaoHNiuWZhangJZhengXLiuYet al. M2 Macrophage-Derived Extracellular Vesicles Containing microRNA-501-3p Promote Colon Cancer Progression through the SETD7/DNMT1/SOCS3 Axis. Dis Colon Rectum. (2023) 66(12):e1234–45. doi: 10.1097/dcr.0000000000002986

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 148

  CuiZLiWWangYZhaoMLiuKYangYet al. M2 macrophage-derived exosomal ferritin heavy chain promotes colon cancer cell proliferation. Biol Trace Elem Res. (2023) 201:3717–28. doi: 10.1007/s12011-022-03488-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 149

  ZhaoMZhouLZhangQWangMDongYWangYet al. Targeting MAPK14 by lobeline upregulates slurp1-mediated inhibition of alternative activation of TAM and retards colorectal cancer growth. Adv Sci (Weinh). (2025) 12:e2407900. doi: 10.1002/advs.202407900

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 150

  BellHNRebernickRJGoyertJSinghalRKuljaninMKerkSAet al. Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance. Cancer Cell. (2022) 40:185–200.e186. doi: 10.1016/j.ccell.2021.12.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 151

  LianQYanSYinQYanCZhengWGuWet al. TRIM34 attenuates colon inflammation and tumorigenesis by sustaining barrier integrity. Cell Mol Immunol. (2021) 18:350–62. doi: 10.1038/s41423-020-0366-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 152

  XieYZhaoYShiLLiWChenKLiMet al. Gut epithelial TSC1/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer. J Clin Invest. (2020) 130:2111–28. doi: 10.1172/jci133264

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 153

  MaisonneuveCTsangDKLFoersterEGRobertLMMukherjeeTPrescottDet al. Nod1 promotes colorectal carcinogenesis by regulating the immunosuppressive functions of tumor-infiltrating myeloid cells. Cell Rep. (2021) 34:108677. doi: 10.1016/j.celrep.2020.108677

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 154

  BaderJEEnosRTVelázquezKTCarsonMSNagarkattiMNagarkattiPSet al. Macrophage depletion using clodronate liposomes decreases tumorigenesis and alters gut microbiota in the AOM/DSS mouse model of colon cancer. Am J Physiol Gastrointest Liver Physiol. (2018) 314:G22–g31. doi: 10.1152/ajpgi.00229.2017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 155

  KangBAlvaradoLJKimTLehmannMLChoHHeJet al. Commensal microbiota drive the functional diversification of colon macrophages. Mucosal Immunol. (2020) 13:216–29. doi: 10.1038/s41385-019-0228-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 156

  BertocchiACarloniSRavendaPSBertalotGSpadoniILo CascioAet al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell. (2021) 39:708–724.e711. doi: 10.1016/j.ccell.2021.03.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 157

  SalvucciMCrawfordNStottKBullmanSLongleyDBPrehnJHM. Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC). Gut. (2022) 71:1600–12. doi: 10.1136/gutjnl-2021-325193

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 158

  Thiele OrbergEFanHTamAJDejeaCMDestefano ShieldsCEWuSet al. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol. (2017) 10:421–33. doi: 10.1038/mi.2016.53

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 159

  WangXYangYMooreDRNimmoSLLightfootSAHuyckeMM. 4-hydroxy-2-nonenal mediates genotoxicity and bystander effects caused by Enterococcus faecalis-infected macrophages. Gastroenterology. (2012) 142:543–551.e547. doi: 10.1053/j.gastro.2011.11.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 160

  KosticADChunERobertsonLGlickmanJNGalliniCAMichaudMet al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. (2013) 14:207–15. doi: 10.1016/j.chom.2013.07.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 161

  YangYWengWPengJHongLYangLToiyamaYet al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21. Gastroenterology. (2017) 152:851–866.e824. doi: 10.1053/j.gastro.2016.11.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 162

  HardbowerDMAsimMLuisPBSinghKBarryDPYangCet al. Ornithine decarboxylase regulates M1 macrophage activation and mucosal inflammation via histone modifications. Proc Natl Acad Sci U S A. (2017) 114:E751–e760. doi: 10.1073/pnas.1614958114

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 163

  FanLXuCGeQLinYWongCCQiYet al. A. Muciniphila suppresses colorectal tumorigenesis by inducing TLR2/NLRP3-mediated M1-like TAMs. Cancer Immunol Res. (2021) 9:1111–24. doi: 10.1158/2326-6066.Cir-20-1019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 164

  ChenJFWuSWShiZMHuB. Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action. Chin Med. (2023) 18:14. doi: 10.1186/s13020-023-00719-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 165

  LiXMYuanDYLiuYHZhuLQinHKYangYBet al. Panax notoginseng saponins prevent colitis-associated colorectal cancer via inhibition IDO1 mediated immune regulation. Chin J Nat Med. (2022) 20:258–69. doi: 10.1016/s1875-5364(22)60179-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166

  YaoYFengSLiXLiuTYeSMaLet al. Litchi procyanidins inhibit colon cancer proliferation and metastasis by triggering gut-lung axis immunotherapy. Cell Death Dis. (2023) 14:109. doi: 10.1038/s41419-022-05482-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 167

  GeSSunXSangLZhangMYanXJuQet al. Curcumin inhibits Malignant behavior of colorectal cancer cells by regulating M2 polarization of tumor-associated macrophages and metastasis associated in colon cancer 1 (MACC1) expression. Chem Biol Drug Des. (2023) 102:1202–12. doi: 10.1111/cbdd.14330

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 168

  ChiouYSLanYMLeePSLinQNagabhushanamKHoCTet al. Piceatannol prevents colon cancer progression via dual-targeting to M2-polarized tumor-associated macrophages and the TGF-β1 positive feedback signaling pathway. Mol Nutr Food Res. (2022) 66:e2200248. doi: 10.1002/mnfr.202200248

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 169

  JiangJZhuFZhangHSunTFuFChenXet al. Luteolin suppresses the growth of colon cancer cells by inhibiting the IL-6/STAT3 signaling pathway. J Gastrointest Oncol. (2022) 13:1722–32. doi: 10.21037/jgo-22-507

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 170

  SunXZhouLWangYDengGCaoXKeBet al. Single-cell analyses reveal cannabidiol rewires tumor microenvironment via inhibiting alternative activation of macrophage and synergizes with anti-PD-1 in colon cancer. J Pharm Anal. (2023) 13:726–44. doi: 10.1016/j.jpha.2023.04.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 171

  YiLWangQLuoHLeiDTangZLeiSet al. Inhibitory effects of polyphenols-rich components from three edible seaweeds on inflammation and colon cancer in vitro. Front Nutr. (2022) 9:856273. doi: 10.3389/fnut.2022.856273

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 172

  HuangMHanYLiLRakariyathamKWuXGaoZet al. Protective effects of non-extractable phenolics from strawberry against inflammation and colon cancer in vitro. Food Chem. (2022) 374:131759. doi: 10.1016/j.foodchem.2021.131759

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173

  XunJHuZWangMJiangXLiuBHanYet al. Hydroxygenkwanin suppresses peritoneal metastasis in colorectal cancer by modulating tumor-associated macrophages polarization. Chem Biol Interact. (2024) 396:111038. doi: 10.1016/j.cbi.2024.111038

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 174

  ZhouMLiRLianGYangMLiLYinZet al. Tetrahydrocurcumin alleviates colorectal tumorigenesis by modulating the SPP1/CD44 axis and preventing M2 tumor-associated macrophage polarization. Phytomedicine. (2025) 141:156674. doi: 10.1016/j.phymed.2025.156674

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 175

  DengZWuNSuoQWangJYueYGengLet al. Fucoidan, as an immunostimulator promotes M1 macrophage differentiation and enhances the chemotherapeutic sensitivity of capecitabine in colon cancer. Int J Biol Macromol. (2022) 222:562–72. doi: 10.1016/j.ijbiomac.2022.09.201

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 176

  GuoMLiZHuangYShiM. Polysaccharides from Nostoc commune Vaucher activate macrophages via NF-κB and AKT/JNK1/2 pathways to suppress colorectal cancer growth in vivo. Food Funct. (2019) 10:4269–79. doi: 10.1039/c9fo00595a

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 177

  WangQHuangYJiaMLuDZhangHWHuangDet al. Safflower polysaccharide inhibits AOM/DSS-induced mice colorectal cancer through the regulation of macrophage polarization. Front Pharmacol. (2021) 12:761641. doi: 10.3389/fphar.2021.761641

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 178

  YangKMGeYPalanisamySZhangYKouFYelithaoKet al. Cnidium officinale polysaccharide enhanced RAW 264.7 cells activation and NK-92 cells cytotoxicity against colon cancer via NF-κB and MAPKs signaling pathways. Int J Biol Macromol. (2023) 253:127605. doi: 10.1016/j.ijbiomac.2023.127605

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 179

  ChengHSunLShenDRenAMaFTaiGet al. Beta-1,6 glucan converts tumor-associated macrophages into an M1-like phenotype. Carbohydr Polym. (2020) 247:116715. doi: 10.1016/j.carbpol.2020.116715

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 180

  KhanIHuangGLiXALiaoWLeongWKXiaWet al. Mushroom polysaccharides and jiaogulan saponins exert cancer preventive effects by shaping the gut microbiota and microenvironment in Apc(Min/+) mice. Pharmacol Res. (2019) 148:104448. doi: 10.1016/j.phrs.2019.104448

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 181

  ShinMSHwangSHYoonTJKimSHShinKS. Polysaccharides from ginseng leaves inhibit tumor metastasis via macrophage and NK cell activation. Int J Biol Macromol. (2017) 103:1327–33. doi: 10.1016/j.ijbiomac.2017.05.055

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182

  McDonaldSJBullardBMVanderVeenBNCardaciTDHussARFanDet al. Panaxynol alleviates colorectal cancer in a murine model via suppressing macrophages and inflammation. Am J Physiol Gastrointest Liver Physiol. (2023) 325:G318–g333. doi: 10.1152/ajpgi.00119.2023

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183

  BaikJSSeoYNYiJMRheeMHParkMTKimSD. Ginsenoside-Rp1 inhibits radiation-induced effects in lipopolysaccharide-stimulated J774A.1 macrophages and suppresses phenotypic variation in CT26 colon cancer cells. J Ginseng Res. (2020) 44:843–8. doi: 10.1016/j.jgr.2020.01.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 184

  LiuFRanFHeHChenL. Astragaloside IV exerts anti-tumor effect on murine colorectal cancer by re-educating tumor-associated macrophage. Arch Immunol Ther Exp (Warsz). (2020) 68:33. doi: 10.1007/s00005-020-00598-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 185

  SenedeseJMRinaldi-NetoFFurtadoRANicollelaHDde SouzaLDRRibeiroABet al. Chemopreventive role of Copaifera reticulata Ducke oleoresin in colon carcinogenesis. BioMed Pharmacother. (2019) 111:331–7. doi: 10.1016/j.biopha.2018.12.091

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 186

  LinYYLeeIYHuangWSLinYSKuanFCShuLHet al. Danshen improves survival of patients with colon cancer and dihydroisotanshinone I inhibit the proliferation of colon cancer cells via apoptosis and skp2 signaling pathway. J Ethnopharmacol. (2017) 209:305–16. doi: 10.1016/j.jep.2017.08.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187

  JiangXCaoGGaoGWangWZhaoJGaoC. Triptolide decreases tumor-associated macrophages infiltration and M2 polarization to remodel colon cancer immune microenvironment via inhibiting tumor-derived CXCL12. J Cell Physiol. (2021) 236:193–204. doi: 10.1002/jcp.29833

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 188

  ZhouJLiYShiXHaoSZhangFGuoZet al. Oridonin inhibits tumor angiogenesis and induces vessel normalization in experimental colon cancer. J Cancer. (2021) 12:3257–64. doi: 10.7150/jca.55929

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 189

  ZhangHZhaoBWeiHZengHShengDZhangY. Cucurbitacin B controls M2 macrophage polarization to suppresses metastasis via targeting JAK-2/STAT3 signalling pathway in colorectal cancer. J Ethnopharmacol. (2022) 287:114915. doi: 10.1016/j.jep.2021.114915

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190

  RuzzoliniJChioccioliSMonacoNPeppicelliSAndreucciEUrciuoliSet al. Oleuropein-rich leaf extract as a broad inhibitor of tumour and macrophage iNOS in an apc mutant rat model. Antioxid (Basel). (2021) 10(10):1577. doi: 10.3390/antiox10101577

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 191

  SougiannisATVanderVeenBChatzistamouIKubinakJLNagarkattiMFanDet al. Emodin reduces tumor burden by diminishing M2-like macrophages in colorectal cancer. Am J Physiol Gastrointest Liver Physiol. (2022) 322:G383–g395. doi: 10.1152/ajpgi.00303.2021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 192

  FanFShenPMaYMaWWuHLiuHet al. Bullatacin triggers immunogenic cell death of colon cancer cells by activating endoplasmic reticulum chaperones. J Inflammation (Lond). (2021) 18:23. doi: 10.1186/s12950-021-00289-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 193

  RohwerNKühlAAOstermannAIHartungNMSchebbNHZopfDet al. Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis. Cancer Med. (2020) 9:2535–50. doi: 10.1002/cam4.2881

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 194

  DongRGongYMengWYuanMZhuHYingMet al. The involvement of M2 macrophage polarization inhibition in fenretinide-mediated chemopreventive effects on colon cancer. Cancer Lett. (2017)388:43–53. doi: 10.1016/j.canlet.2016.11.029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195

  NatoliMHerzigPPishali BejestaniEBuchiMRitschardRLloydGKet al. Plinabulin, a distinct microtubule-targeting chemotherapy, promotes M1-like macrophage polarization and anti-tumor immunity. Front Oncol. (2021) 11:644608. doi: 10.3389/fonc.2021.644608

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196

  OhnoYToshinoMMohammedAFAFujiwaraYKomoharaYOnoderaRet al. Mannose-methyl-β-cyclodextrin suppresses tumor growth by targeting both colon cancer cells and tumor-associated macrophages. Carbohydr Polym. (2023) 305:120551. doi: 10.1016/j.carbpol.2023.120551

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 197

  LvQPanXWangDRongQMaBXieXet al. Discovery of (Z)-1-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)-3-(isoxazol-3-yl)urea derivatives as novel and orally highly effective CSF-1R inhibitors for potential colorectal cancer immunotherapy. J Med Chem. (2021) 64:17184–208. doi: 10.1021/acs.jmedchem.1c01184

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 198

  ChunJParkSMLeeMHaIJJeongMK. The sesquiterpene lactone-rich fraction of inula helenium L. Enhances the antitumor effect of anti-PD-1 antibody in colorectal cancer: integrative phytochemical, transcriptomic, and experimental analyses. Cancers (Basel). (2023) 15(3):653. doi: 10.3390/cancers15030653

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 199

  ChanASHKangasTOQiuXUhlikMTFultonRBOttosonNRet al. Imprime PGG enhances anti-tumor effects of tumor-targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies. Front Oncol. (2022) 12:869078. doi: 10.3389/fonc.2022.869078

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 200

  ZhangGPanJXuXNieSLuLJingYet al. Chinese yam polysaccharide enhances anti-PD-1 immunotherapy in colorectal cancer through alterations in the gut microbiota and metabolites. Int J Biol Macromol. (2025) 310:143323. doi: 10.1016/j.ijbiomac.2025.143323

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 201

  SuYChoiHSChoiJHKimHSJangYSSeoJW. 7S,15R-dihydroxy-16S,17S-epoxy-docosapentaenoic acid overcomes chemoresistance of 5-fluorouracil by suppressing the infiltration of tumor-associated macrophages and inhibiting the activation of cancer stem cells in a colorectal cancer xenograft model. Mar Drugs. (2023) 21(2):80. doi: 10.3390/md21020080

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 202

  WangLChoiHSSuYLeeBSongJJJangYSet al. 7S,15R-dihydroxy-16S,17S-epoxy-docosapentaenoic acid, a novel DHA epoxy derivative, inhibits colorectal cancer stemness through repolarization of tumor-associated macrophage functions and the ROS/STAT3 signaling pathway. Antioxid (Basel). (2021) 10(9):1459. doi: 10.3390/antiox10091459

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 203

  HuangYJYangCKWeiPLHuynhTTWhang-PengJMengTCet al. Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways. J Hematol Oncol. (2017) 10:60. doi: 10.1186/s13045-017-0421-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 204

  GuoPHuangJMosesMA. Cancer nanomedicines in an evolving oncology landscape. Trends Pharmacol Sci. (2020) 41:730–42. doi: 10.1016/j.tips.2020.08.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 205

  ZhangZJiYHuNYuQZhangXLiJet al. Ferroptosis-induced anticancer effect of resveratrol with a biomimetic nano-delivery system in colorectal cancer treatment. Asian J Pharm Sci. (2022) 17:751–66. doi: 10.1016/j.ajps.2022.07.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 206

  PengJZhouJSunRChenYPanDWangQet al. Dual-targeting of artesunate and chloroquine to tumor cells and tumor-associated macrophages by a biomimetic PLGA nanoparticle for colorectal cancer treatment. Int J Biol Macromol. (2023) 244:125163. doi: 10.1016/j.ijbiomac.2023.125163

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 207

  LvYLiMWengLHuangHMaoYYangDAet al. Ginseng-derived nanoparticles reprogram macrophages to regulate arginase-1 release for ameliorating T cell exhaustion in tumor microenvironment. J Exp Clin Cancer Res. (2023) 42:322. doi: 10.1186/s13046-023-02888-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 208

  de CarvalhoTGLaraPJorquera-CorderoCAragãoCFSde Santana OliveiraAGarciaVBet al. Inhibition of murine colorectal cancer metastasis by targeting M2-TAM through STAT3/NF-kB/AKT signaling using macrophage 1-derived extracellular vesicles loaded with oxaliplatin, retinoic acid, and Libidibia ferrea. BioMed Pharmacother. (2023) 168:115663. doi: 10.1016/j.biopha.2023.115663

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 209

  ChengFHeLWangJLaiLMaLQuKet al. Synergistic immunotherapy with a calcium-based nanoinducer: evoking pyroptosis and remodeling tumor-associated macrophages for enhanced antitumor immune response. Nanoscale. (2024) 16:18570–83. doi: 10.1039/d4nr01497a

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 210

  LiXWuMWuYXinYGaoLElsabahyMet al. Multifunctional nanodrug for simultaneously combating chemoresistance and immunosuppression in Fusobacterium nucleatum-associated colorectal cancer. Acta Biomater. (2025) 195:406–20. doi: 10.1016/j.actbio.2025.02.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 211

  AbdiHArabiLMontazerMAskarizadehAZamaniPHosseinzadehHet al. The effect of m2 peptide targeted nanoliposomes containing crocin on induction of phenotypic change in tumor macrophages to M1 state. Life Sci. (2023) 330:121992. doi: 10.1016/j.lfs.2023.121992

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 212

  MaLMaYGaoQLiuSZhuZShiXet al. Mulberry leaf lipid nanoparticles: a naturally targeted CRISPR/cas9 oral delivery platform for alleviation of colon diseases. Small. (2024) 20:e2307247. doi: 10.1002/smll.202307247

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 213

  HamaSNishiTIsonoEItakuraSYoshikawaYNishimotoAet al. Intraperitoneal administration of nanoparticles containing tocopheryl succinate prevents peritoneal dissemination. Cancer Sci. (2022) 113:1779–88. doi: 10.1111/cas.15321

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 214

  DuttaDAl HoqueAPaulBParkJHChowdhuryCQuadirMet al. EpCAM-targeted betulinic acid analogue nanotherapy improves therapeutic efficacy and induces anti-tumorigenic immune response in colorectal cancer tumor microenvironment. J BioMed Sci. (2024) 31:81. doi: 10.1186/s12929-024-01069-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 215

  JúniorRFALiraGASchomannTCavalcanteRSVilarNFde PaulaRCMet al. Retinoic acid-loaded PLGA nanocarriers targeting cell cholesterol potentialize the antitumour effect of PD-L1 antibody by preventing epithelial-mesenchymal transition mediated by M2-TAM in colorectal cancer. Transl Oncol. (2023) 31:101647. doi: 10.1016/j.tranon.2023.101647

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 216

  ChengGZhangXChenYLeeRJWangJYaoJet al. Anticancer activity of polymeric nanoparticles containing linoleic acid-SN38 (LA-SN38) conjugate in a murine model of colorectal cancer. Colloids Surf B Biointerfaces. (2019) 181:822–9. doi: 10.1016/j.colsurfb.2019.06.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 217

  SpyridopoulouKAindelisGPappaAChlichliaK. Anticancer activity of biogenic selenium nanoparticles: apoptotic and immunogenic cell death markers in colon cancer cells. Cancers (Basel). (2021) 13(21):5335. doi: 10.3390/cancers13215335

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 218

  MaoQMinJZengRLiuHLiHZhangCet al. Self-assembled traditional Chinese nanomedicine modulating tumor immunosuppressive microenvironment for colorectal cancer immunotherapy. Theranostics. (2022) 12:6088–105. doi: 10.7150/thno.72509

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 219

  SuiHTanHFuJSongQJiaRHanLet al. The active fraction of Garcinia yunnanensis suppresses the progression of colorectal carcinoma by interfering with tumorassociated macrophage-associated M2 macrophage polarization in vivo and in vitro. FASEB J. (2020) 34:7387–403. doi: 10.1096/fj.201903011R

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 220

  ChaiNXiongYZhangYChengYShiWYaoYet al. YYFZBJS inhibits colorectal tumorigenesis by remodeling gut microbiota and influence on M2 macrophage polarization in vivo and in vitro. Am J Cancer Res. (2021) 11:5338–57. doi: 10.2139/ssrn.3837225

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 221

  ZhouJYChenMWuCEZhuangYWChenYGLiuSL. The modified Si-Jun-Zi Decoction attenuates colon cancer liver metastasis by increasing macrophage cells. BMC Complement Altern Med. (2019) 19:86. doi: 10.1186/s12906-019-2498-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 222

  ZhaoLZhuXNiYYouJLiA. Xiaoyaosan, a traditional Chinese medicine, inhibits the chronic restraint stress-induced liver metastasis of colon cancer in vivo. Pharm Biol. (2020) 58:1085–91. doi: 10.1080/13880209.2020.1839513

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 223

  MaELChoiYJChoiJPothoulakisCRheeSHImE. The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. Int J Cancer. (2010) 127:780–90. doi: 10.1002/ijc.25011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 224

  SunMLiuWSongYTuoYMuGMaF. The effects of lactobacillus plantarum-12 crude exopolysaccharides on the cell proliferation and apoptosis of human colon cancer (HT-29) cells. Probiotics Antimicrob Proteins. (2021) 13:413–21. doi: 10.1007/s12602-020-09699-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 225

  YueYWangSShiJXieQLiNGuanJet al. Effects of lactobacillus acidophilus KLDS1.0901 on proliferation and apoptosis of colon cancer cells. Front Microbiol. (2021) 12:788040. doi: 10.3389/fmicb.2021.788040

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 226

  YueYYeKLuJWangXZhangSLiuLet al. Probiotic strain Lactobacillus plantarum YYC-3 prevents colon cancer in mice by regulating the tumour microenvironment. BioMed Pharmacother. (2020) 127:110159. doi: 10.1016/j.biopha.2020.110159

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 227

  HradickaPBealJKassayovaMFoeyADemeckovaV. A novel lactic acid bacteria mixture: macrophage-targeted prophylactic intervention in colorectal cancer management. Microorganisms. (2020) 8(3):387. doi: 10.3390/microorganisms8030387

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 228

  ZhuoQYuBZhouJZhangJZhangRXieJet al. Lysates of Lactobacillus acidophilus combined with CTLA-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer model. Sci Rep. (2019) 9:20128. doi: 10.1038/s41598-019-56661-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 229

  BinmamaSDangCPVisitchanakunPHiengrachPSomboonnaNCheibchalardTet al. Beta-Glucan from S. cerevisiae Protected AOM-Induced Colon Cancer in cGAS-Deficient Mice Partly through Dectin-1-Manipulated Macrophage Cell Energy. Int J Mol Sci. (2022) 23(18):10951. doi: 10.3390/ijms231810951

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 230

  XuXQiaoYPengQShiB. Probiotic properties of loigolactobacillus coryniformis NA-3 and in vitro comparative evaluation of live and heat-killed cells for antioxidant, anticancer and immunoregulatory activities. Foods. (2023) 12(5):1118. doi: 10.3390/foods12051118

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 231

  DragoL. Probiotics and colon cancer. Microorganisms. (2019) 7(3):66. doi: 10.3390/microorganisms7030066

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 232

  JakubauskasMJakubauskieneLLeberBHorvathAStrupasKStieglerPet al. Probiotic supplementation attenuates chemotherapy-induced intestinal mucositis in an experimental colorectal cancer liver metastasis rat model. Nutrients. (2023) 15(5):1117. doi: 10.3390/nu15051117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 233

  MahdyMSAzmyAFDishishaTMohamedWRAhmedKAHassanAet al. Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity. BMC Microbiol. (2023) 23:53. doi: 10.1186/s12866-023-02791-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 234

  YangJWeiHZhouYSzetoCHLiCLinYet al. High-fat diet promotes colorectal tumorigenesis through modulating gut microbiota and metabolites. Gastroenterology. (2022) 162:135–149.e132. doi: 10.1053/j.gastro.2021.08.041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 235

  ZhangNLiuCJinLZhangRWangTWangQet al. Ketogenic diet elicits antitumor properties through inducing oxidative stress, inhibiting MMP-9 expression, and rebalancing M1/M2 tumor-associated macrophage phenotype in a mouse model of colon cancer. J Agric Food Chem. (2020) 68:11182–96. doi: 10.1021/acs.jafc.0c04041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 236

  LiZZhangSZhangYChenJWuFLiuGet al. Applications and mechanism of 3-hydroxybutyrate (3HB) for prevention of colonic inflammation and carcinogenesis as a food supplement. Mol Nutr Food Res. (2021) 65:e2100533. doi: 10.1002/mnfr.202100533

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 237

  JanakiramNBMohammedABryantTLightfootSCollinPDSteeleVEet al. Improved innate immune responses by Frondanol A5, a sea cucumber extract, prevent intestinal tumorigenesis. Cancer Prev Res (Phila). (2015) 8:327–37. doi: 10.1158/1940-6207.Capr-14-0380

  • Pubmed Abstract
  • CrossRef
  • Google Scholar